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The UK is a world leader in genomic medicine, with plans to collect 5 million genomes by 2024. 
The use of genetic data in healthcare is posited to bring many benefits to UK healthcare. 
 
However, genetics is not widely understood by the public. The deficit model of knowledge 
suggests that misunderstandings about genetics are likely to be linked to a lack of acceptance of 
genomic medicine. It is important to characterise the nature of this relationship as this will help 
to guide mainstreaming of genetic testing into NHS practice. Previous studies examining this 
relationship show mixed results; the nature of the relationship may depend on the specific type 
of knowledge studied. Therefore, my first study explored UK participants’ biological knowledge 
of genetics, their clinical knowledge of genomic medicine, and their perception of their genetic 
knowledge. The results indicated that neither biological nor clinical knowledge predicted 
participants’ acceptance of genomics. However, participants’ perception of their own genetic 
knowledge was found to predict their acceptance. This suggests that to increase acceptance, we 
should focus our resources on ensuring the public are confident in their knowledge.  
 
My second study was a qualitative exploration of participants’ opinions about genomic medicine. 
Participants were given information about genomic medicine prior to the study. The results 
indicated that although participants recognised some benefits of genomic medicine, they also 
had concerns. For example, whilst genetic data were considered to have the ability to empower 
you to live your life to the full, participants were also concerned about the potential for genetic 
results to have a detrimental psychological impact. Overall, the results pointed to the importance 
of genetic counsellors and maintaining anonymity throughout the genetic testing process, as 
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1.1 Thesis motivation 
My undergraduate dissertation findings indicated a growing interest in the use of genomic 
medicine within the UK National Health Service (NHS). This triggered my interest in the 
public’s perception of the use of genetic data in healthcare. I wanted to offer a useful 
contribution as to how we can improve public acceptance of genomic medicine, and deliver an 
up-to-date insight into public opinion, particularly as the 100,000 Genomes Project was set to 
finish two months into my MSc. I decided on a mixed methods approach because it would allow 
for the collection of rich data. It also meant I could focus on developing my skills in both 
quantitative and qualitative methodology.  
 
1.1.1     Collaboration with West of England Genomic Medicine 
Centre 
Throughout my MSc, I have collaborated with the West of England Genomic Medicine Centre 
(GMC). This gave me a useful insight into the reality of integrating genomics into healthcare 
and the difficulties associated. One of these difficulties concerned the consent process for 
undertaking genetic testing in a clinical setting. The GMC wanted to improve its understanding 
of current public views so that the development of consent materials could incorporate the 
opinions of those it would affect. Through the current thesis and additional collaborative work, 
I hope to help inform their consent process. 
 
1.2   Thesis overview 
In this thesis, I aimed to explore the relationship between knowledge of genetics and 
acceptance of genomics in the NHS. Previous research indicates the specific type of scientific 
knowledge studied is important when exploring the relationship between knowledge and 
acceptance (Allum et al. 2008). I aimed to explore three different aspects of knowledge: 
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biological, i.e. knowledge of genes and how they work in the body, clinical, i.e. an awareness of 
the current situation of genomic medicine in the UK, and perception of knowledge, i.e. how 
confident participants are in their understanding of genetics. I am not aware of any studies that 
have explored clinical knowledge. Instead, previous studies have focused on biological 
knowledge (Allum et al. 2014; Human Genetics Commission, 2001; Jallinjoa & Aro, 2000), 
which misses out on real world applications of knowledge. I also conducted a qualitative 
investigation into public opinion on the use of genetic data in healthcare. I believe this is one of 
the first studies to study the public’s opinion of clinical genetics after informing participants 
about genomics beforehand; this allowed us to gather opinions that are not based on false 
information and ideas.  
 
The importance of investigations using members of the public has been demonstrated multiple 
times (Davies, 2017; Haga & Willard, 2006; Henneman et al. 2013; Samuel & Farsides, 2018); it 
may uncover gaps in knowledge or sources of uncertainty that can help to develop more 
effective communication and maximise the probability that policies will generate satisfaction 
in all stakeholders. Therefore, based on data from the public, this thesis aims to provide a 
valuable input to the integration of genomics into the NHS. 
 
1.3   The human genome and genomic medicine 
A genome is the entire set of genetic material in a cell and encompasses all of the information 
required to build and maintain an organism (Genetics Home Reference, 2019). 
Deoxyribonucleic acid (DNA) contains 4 nucleotides bases that pair up: adenine (A) pairs with 
thymine (T), and cytosine (C) pairs with guanine (G). A human genome has approximately 3 
billion of these nucleotide base pairs (National Human Genome Research Institute, 2018).  
 
Whole genome sequencing (WGS) is a technology that allows researchers to decipher the exact 
order of the letters - A, T, C and G - in a genome (Icahn School of Medicine, 2012). This can: 
reveal information about an individual’s risk of disease, help to give an accurate diagnosis for a 
pre-existing condition, or indicate the most effective choice of medical treatment (NHGRI, 
2018). This has been labelled ‘genomic medicine’. 
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Globally, the NHS is the single largest integrated healthcare system (NHS England, 2018a), i.e. 
NHS organisations collaborate with external organisations and benefit from their expertise to 
deliver high quality healthcare (NHS England, n.d). Therefore, the NHS (2018a) recognises the 
potential for genomics not only to benefit patients but, through collaboration with the life 
sciences industry, propel the UK’s understanding of disease and its ability to develop medical 
tools for early detection and effective treatment. 
 
1.4  History of genomic medicine 
In 1990, sequencing the human genome took 13 years of research and cost, at minimum, $500 
million (National Human Genome Research Institute, 2019). In 2012, the 100,000 Genomes 
Project was launched, which was the first genomic project to focus on the integration of 
genomic data into healthcare (PHG Foundation, 2012). Today, we can sequence a genome in a 
single day for £700 or less (Turnbull et al. 2018) and the UK has just launched the world’s first 
genomic medicine service (Genetic Alliance UK, 2018). To illustrate the speed at which our 
knowledge of genomics has developed, I have outlined a timeline of the last 30 years of 
genomic sequencing and its use in healthcare (Figure 1). Further detail of the significant time 
points can be found below. 
  
• 1990: The Human Genome Project officially began. The National Human Genome 
Research Institute recognised this was an international effort to identify the entire 
sequence of nucleotide base pairs in human DNA (NHGRI, 2013).  
 
• 2003: Two years earlier than anticipated, the Human Genome Project was completed. 
Due to limited technology, the finished sequence had a few small gaps however 
consisted of 99% of the genome and was 99.99% accurate (NHGRI, 2014). 
 
• 2008:  Another international collaboration was launched: 1,000 Genomes Project. The 
aim was to identify genetic variants, i.e. changes in the most common sequence of 
nucleotide bases in DNA, with frequencies of ≥1% from multiple populations (1000 
Genomes Project Consortium, 2015).  
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• 2012: The UK Government announced a 3-5 year plan to sequence 100,000 genomes 
from patients with a rare disease or cancer (PHG Foundation, 2012). This project 
shifted genomic sequencing into the medical world.  
 
• 2015: The completion of the 1,000 Genomes Project (1000 Genomes Project 
Consortium, 2015) provided a useful and publicly available resource of human genetic 
variation and reduced sequencing costs (International Genome Sample Resource, 2018). 
 
• 2018: The completion of transformational 100,000 Genomes Project helped to diagnose 
approximately 25% of the participants with a rare disease, delivered actionable 
information for some cancer patients, and provided a vast store of genomic and clinical 
data for research (Genomics England, 2018).   
 
In October 2018, the NHS genomic medicine service was initiated. This service aims to 
integrate WGS into the mainstream care of patients with a rare inherited disease or 
cancer (Turnbull et al. 2018). Further, to enable a more systematic approach to genomic 
medicine, the NHS has created a National Genomic Test Directory that details the type 
and eligibility criteria of available tests (NHS England, 2019). 
 
Figure 1 Timeline of genomic sequencing from 1990 to 2018. 
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1.5  The current state of genetics in healthcare  
1.5.1   100,000 Genomes Project – what next? 
Off the back of the successful 100,000 Genomes Project, the Government has announced an 
ambitious plan to sequence 5 million genomes by 2024 (Department of Health and Social Care, 
2018). This will be a collaborative effort between the NHS, industry experts and research 
projects (the NHS and UK Biobank are expected to sequence 1 million genomes). To help reach 
this target, patients with a rare disease or certain types of cancer will continue to be offered 
WGS on the NHS, with the option to donate their data to research. This offer will also be made 
to seriously ill children. Further, the NHS considered offering healthy individuals the 
opportunity to pay for WGS (Photopoulos, 2019). Upon concerns that this would create a two-
tier healthcare system, the Government have now announced plans to sequence the DNA of 5 
million healthy volunteers for free (Sample, 2019).  
 
Now, there are 3000+ researchers worldwide working on genomics, with the key aim to 
understand more about disease before it develops (Caulfield, 2019). Also, genomic medicine is 
being integrated into mainstream healthcare. This means that clinical specialists will have to 
order genetic tests and communicate the test results to patients. To make this transition easier, 
clinicians will use the National Genomic Test Directory to ascertain patients’ eligibility for 











1.5.2     What genetic tests do the NHS currently use? 
The NHS already offers genetic testing in certain circumstances, summarised below. 
 
1.5.2.1  High penetrance mutations 
These are genetic mutations that are likely to be phenotypically expressed (Griffiths et al. 
2005). For example, a mutation in one of the tumour-suppressing genes BRCA1 or BRCA2 can 
increase a woman’s risk of developing breast cancer from the average of 12% to approximately 
70% (National Cancer Institute, 2018). Patients are eligible for genetic testing if they have a 
family history of cancer and/or a relative with the mutation (NHS England, 2018b). 
 
1.5.2.2  Monogenic disorders 
These are disorders that derive from a single version of a gene. If a patient carries particular 
mutations of the gene, they will definitely develop the disease at some point. An example is 
Huntington’s disease: those with a family history are eligible for genetic testing on the NHS 
(Huntington’s Disease Association, 2019).  
 
1.5.2.3  Cancer 
The existence of particular mutations in a cancer can indicate the most effective treatment 
interventions for a patient (Dancey et al. 2012). Genomic testing to improve our understanding 
of a cancer’s genetic base is fairly common and is used for a range of cancers, including brain, 
breast, and skin, as well as colon cancer and leukaemia (NHS England, 2016).  
 
1.5.3 Genomics – a controversial topic 
The unique arrangement of the NHS and its position as the world’s largest integrated 
healthcare system currently enables vast numbers of patients to reap the benefits of genomic 
medicine (NHS England, 2018). However, genomic medicine opens up key ethical challenges as 
it is an approach to healthcare in which there is something of a grey area between research and 
clinical care: data obtained for research purposes may lead to findings of clinical significance, 
and patients can consent to the sharing of their genetic data for research purposes (Bertier, 
Cambon-Thomsen, & Yoly, 2018). Hallowell (2018) recognised that the ethical guidelines for 
both disciplines are distinct and, as of yet, no new ethical model has been implemented that 
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sees the convergence of the two domains. The question of whether patients have a 
responsibility to participate in research, and what this means for the consent process, has been 
debated. 
 
Further, genomic data is unique because it can have implications for genetically related family 
members and can reveal unexpected findings. Consequently, WGS tests traditional ideas of 
consent and confidentiality. This is explored further below. 
 
1.5.3.1 Confidentiality 
Confidentiality is threatened by: 
 
1.5.3.1.1  Genetic relatedness between individuals  
Unlike other clinical tests, genetic tests can have implications for family members. Generally, 
confidentiality can be broken if there is an immediate threat to the life of another person; 
whether or not genetic test results represent such an immediate threat is debatable (Badzek et 
al. 2013). The complex ethical situation surrounding the legal responsibility of the doctor to 
provide a duty of care to one patient but also to maintain another patient’s privacy is 
demonstrated in a recent legal case. In summary, a patient has brought a legal case against a 
hospital because they chose not to inform her about her father’s Huntington’s gene (Dyer, 
2015). After her father’s death, the patient discovered that she too carries the version of the 
gene for the hereditary disease and that her 8-year-old daughter has a 50% chance of carrying 
it. The patient states she would have had an abortion if she had known. This case will come to 
trial in November 2019 and may lead to changes in law regarding patient-doctor relationships. 
 
A recent exploration of public opinion into this case indicated that a large majority of 
participants thought that, morally, the father should have told his daughter (Chapman et al. 
2018). However, opinions were more polarized when asked about the daughter’s right to the 
information and about whether the onus was on the NHS to disclose the genetic information. 
Indeed, 25% of participants believed that the NHS had no legal obligation to do so, whilst 35% 
of participants answered that the NHS ‘absolutely’ did. Overall, the authors concluded that such 
strong, polarised views indicated that the issues raised by the genetic relatedness between 
individuals are both complex and contentious. 
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1.5.3.1.2 Sharing clinical data  
For genomic data to have clinical utility, it must be linked to patients’ private medical records. 
This will help to unravel the complex relationship between genetics, what happens to us in our 
lives, and illness. This access requires the sharing of data across both national and 
international services. Indeed, plans to offer every patient the opportunity to participate in 
research and thus contribute to the National Genomic Data Resource demonstrates the need 
for the central collection of data (Hill, 2018). 
 
 
1.5.3.2        Consent 
WGS can reveal findings of diagnostic significance that are unconnected to the original reason 
for the genetic test (Mackley & Capps, 2017); some are sought out whilst others can be found 
unintentionally (Roche & Berg, 2015). Such ‘additional findings’ make the process of informed 
consent difficult.  
 
The argument against informing patients of these findings is that, particularly if unactionable, 
i.e. no available medical intervention, they can cause psychological harm and distress (Ali-Khan 
et al. 2009) and may overload patients with information (Cho, 2008). However, if actionable, 
i.e. medical intervention is available, findings may inform treatment and improve patient 
choice (Caulfield et al. 2008). Indeed, a systematic review suggested these findings should be 
revealed if there is the possibility of effective treatment (Christenhusz, Devriendt & Dierickx, 
2013). However, in a research setting without a duty of care, it is questionable whether we 
should be actively looking for these finding at all (Mackley & Capps, 2017). Further, it is very 
rare for researchers to return findings to patients as data is usually anonymised in research, so 
this must be consented to beforehand. For example, 100,000 Genomes Project participants had 
to opt in for the researchers to look for additional findings (Genomics England, 2018). These 
participants may receive these additional findings in several years time, as our knowledge of 
the human genome and the role of genes in disease expands, thus challenging the notion of 
‘informed’ consent. This is complicated further by research that shows 54% of patients expect 





Further, young children are unable to provide informed consent regarding whether or not to 
have a genetic test, and yet the outcome has the potential to completely alter the course of 
their life (Selita, 2019). Similarly, informed consent is not possible without genetic knowledge 
or an understanding of all potential uses of their data. However, research shows poor levels of 
genetic knowledge even amongst the well-educated (Chapman et al. 2017) and organisations 
outside of the original institution have often been allowed third party access to data (Selita, 
2019).  
 
Overall, due to the range of possible findings (e.g. monogenic disorder versus carrier status), 
the implications for relatives, our limited but growing knowledge of the effects of individual 
genetic variants, as well as the difficulties surrounding the very notion of ‘informed’ consent, it 
is difficult to design a single consent protocol for ‘additional findings’ in healthcare (Mackley & 
Capps, 2017).   
 
The next section will explore the extent of the public’s understanding and knowledge of 
genetics. 
 
1.6 Public knowledge & understanding of genetics 
1.6.2     Summary of the literature 
Studies indicate that research participants have relatively little knowledge of basic genetic 
concepts (Chapman et al. 2019; Haga et al. 2013; Lanie et al. 2004; Richards, 2016; Walter et al. 
2004). Indeed, one study found a mere 1.2% of participants were able to correctly answer all 
18 basic genetic literacy questions, and that those from the UK scored significantly lower than 
US participants (Chapman et al. 2019). Below is a summary of the main nuances and 
complexities of the public’s understanding of genetics. 
 
1.6.2.1     Heredity versus molecular genetics 
The public display a better understanding of the genetic relatedness between family members 
(Kessler, Collier, & Halbert, 2007) and the fact that we inherit traits from our parents (Catz et 
al. 2005; Molster et al. 2009) than their understanding of the structure and/or function of 
genes. Other studies have also shown there is a greater understanding of heredity than there is 
of molecular genetics (Christensen et al. 2010; Haga et al. 2013; Lanie et al. 2004). For example, 
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in a survey of 300 participants aged 18-70, scores were considerably better on questions 
concerning the inheritance of disease than on questions on chromosomes and cells (Haga et al. 
2013).  
 
1.6.2.2      The role of personal experience 
Personal experience of a health condition, e.g. a family member having a disease, can shape 
how an individual perceives its causal nature and hence their risk for it (Lucke et al. 2008; 
Walter et al. 2004). Indeed, Walter et al’s (2004) meta-analysis explored the personalisation 
process of familial disease risk. The researchers found that an individual’s perceived 
vulnerability to genetic disease was influenced by their relative’s premature death or disability, 
their age at death and/or gender, and their emotional closeness to the relative.  
 
More general personal experiences and beliefs also shape people’s understanding of disease. 
For example, when unsure about the genetic relatedness of extended family members, people 
guess based on the strength of the social relationship (Richards, 2016), i.e. people with whom 
they are emotionally closer to are seen as more genetically related. Further, the public tend to 
choose causal variables of disease depending on their personal beliefs. For example, a study 
found that smokers were largely sceptical of a media story concerning the detection of a 
genetic variant linked to heightened nicotine addiction (Waters, Ball & Gehlert, 2017). The 
smokers’ mistrust arose when their own beliefs about genetics clashed with the scientific 
evidence presented to them. 
 
1.6.2.3    Physical versus behavioural traits 
Research shows that the public believe that behavioural traits are more strongly associated 
with the environment, whereas physical traits are more strongly associated with genetics 
(Condit et al. 2004; Lanie et al. 2004). This is consistent with previous research that indicates 
perceptions of genetic attribution follow a certain pattern (Morin-Chassé, 2014; Parrott, Silk, & 
Condit, 2003; Shostak et al. 2009): the more biological a trait is, the bigger the perceived role of 
genetics in affecting that trait. Interestingly, people display the most confidence when 
estimating the genetic attribution of traits that are either highly associated with biology, e.g. 
height, or far from biology, e.g. being liberal or conservative (Morin-Chassé, 2014).  
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1.6.2.4      Gene-environment interaction & genetic determinism 
The public perceive the role of both genetics and the environment to be important, however 
struggle to understand that these two factors can interact (Condit & Shen, 2011; Condit et al. 
2009; French et al. 2000). French et al’s (2000) study found participants regarded people who 
smoke or who have a family history of heart disease as very likely to experience a heart attack. 
However, when both risk factors were combined, participants did not increase their 
estimations, i.e. did not consider a gene-environment interaction.  
 
Further, whilst some qualitative research indicates people have some implicit grasp of gene-
environment interaction (Lanie et al. 2004), other qualitative research shows that once an 
individual decides a condition is behaviourally motivated, they consequently find it difficult to 
comprehend an alternative causal factor (Morris et al. 2003). Contrastingly, other research 
shows that most early adopters of personalised genomics exhibited a refined knowledge of the 
interaction between genes and environment (Gollust et al. 2012). However, the participants’ 
status as early adopters of personalised genomics differentiates them from the average 
member of public who may not have even heard of ‘personalised genomics’. 
 
The inability to understand the interaction between genes and environment is tied in with 
‘genetic determinism’ – the belief that a version of a gene for a trait will always lead to the 
development of that trait, rather than merely increasing the probability of its occurrence 
(Resnik & Vorhaus, 2006). Whilst some research shows the public display beliefs consistent 
with genetic determinism (Lanie et al. 2004; Parrott et al. 2012) other research found this 
belief to differ depending on the sample.  For example, genetic determinism has been found 
more often in people who hold discriminatory beliefs, such as racism and sexism (Condit, 
2011), or people who have less genetic knowledge (Chapman et al. 2019). 
 
 
1.6.2.4.1  Impact of the media on beliefs of genetic determinism 
Research into the impact of media reports of genetics shows an effect that is more subtle than 
an immediate endorsement of beliefs consistent with genetic determinism (Morin-Chassé, 
2018). With reports of medical genetics, people accept a single, specific finding and adjust their 
genetic beliefs regarding that single, specific condition accordingly, e.g. breast cancer or 
diabetes (Smerecnik, 2010). However, with media reports of findings in behavioural genetics, 
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the public extrapolate the perceived importance of genetics to other, unmentioned traits, e.g. 
generalising a genetic finding related to violent behaviour to gambling addictions (Morin-
Chassé, 2014). An increase in genetic determinism is harmful not only because it goes against 
scientific knowledge, but also because it can reinforce pre-existing intolerant attitudes (Gericke 
et al. 2017).  
 
Regardless of the source of the public’s misunderstandings, it is essential that we develop an 
understanding of the way in which peoples’ knowledge of genetics affects their acceptance of 
genomic medicine. The following section will explore the public’s attitudes towards genomics 
and demonstrate the importance of encouraging support for genomic medicine. 
 
1.7 Public opinion of & attitudes towards genetic data 
1.7.1 Review of the literature 
A study in 1995 found that the general public views genetics as a ‘double edged sword’ (Michie 
et al. 1995, pg. 250). Indeed, due to the controversial nature of genomics (see section 1.5.3) this 
perspective has largely been maintained, with more recent research demonstrating the public 
still see genomic medicine as representing both great potential and great risk (Henneman et al. 
2013; Wellcome Trust, 2016). Below is a summary of the literature regarding the public’s main 
concerns and perceived benefits of genomic medicine. 
 
1.7.1.1 Concern: commercialisation 
One concern surrounding the use of genetic data in healthcare arises from the potential for 
these data to be used by commercial companies without obvious benefit to the public (Trinidad 
et al. 2010); 30.7% of participants in one study were concerned about their genetic data being 
used for marketing (Middleton et al. 2019).  Another study found that 17% of participants 
would opt against commercial companies using their health data for any kind of research 
(Wellcome Trust, 2016). In the same study, 25% of participants indicated their concerns 
regarding data sharing outweighed the potential benefits from research, and 54% of 
participants indicated their highest priority was that the NHS sought permission for the 
commercialisation of their data - even if this meant that research would be halted. Similarly, 
Hapgood et al. (2004) found that the single most significant factor in deciding whether to 
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participate in UK Biobank was access to data; participants were content with the NHS and 
universities accessing their data but displayed dissatisfaction with access by third parties, e.g. 
pharmaceutical companies.  
 
A potential source of this discontent could be the lack of public trust regarding commercial 
entities (Chalmers & Nicol, 2004; Ford et al. 2017; Levitt & Weldon, 2005). Indeed, one study 
found that for 94% of participants, their level of trust in an organisation would influence 
whether they would share their data with it (Open Data Institute, 2018). Another source of the 
dislike of commercial companies may be the belief that combining medical work with 
monetary benefit is ethically questionable (Haddow et al. 2007); some people believe that 
companies should not gain commercial benefit from patients’ donations of their genomic data. 
 
Further, whilst some research discovered that the public are usually more aware of 
commercial companies’ role than is widely believed (Aitken, Cunningham-Burley & Pagliari, 
2016), other studies show a lack of public understanding regarding the NHS’s reasons for 
collaborating with commercial companies and how these companies use the data and play a 
part in healthcare (Castle-Clarke, 2018; Wellcome Trust, 2016). In fact, higher levels of 
acceptance of commercial companies has been linked to being more informed about how the 
data would be used (Jack & Womack, 2003; Wellcome Trust, 2016).  
 
1.7.2.2    Concern: discrimination 
A second common concern is the risk of discrimination and/or misuse of health data when it is 
used in research (Anderson, 2015). Despite many legal protections against it (Middleton, 
2018), the fear of genetic discrimination is significant amongst the public (Wauters & Van 
Hoyweghen, 2016). Some research indicates that the concern that a dichotomous society could 
arise, with some people having ‘good genes’ and others having ‘bad genes’, has actually 
increased over the years (Henneman et al. 2013). In fact, public concerns that genetic 
discrimination could arise at a societal level in the form of a eugenics-like movement has been 
found in multiple studies (Fox, 2002; Geller, Bernhardt, & Holtzman, 2002; Gottweis, 2002; 
Vines, 1997).  
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On an individual level, participants have cited as a major concern firstly the potential for the 
NHS to prioritise other patients due to their genetics (Shickle, 1997; Wellcome Trust, 2013), 
and secondly the possibility that genetic results may lead to increases in insurance costs (Cook, 
1999; Geer et al. 2001; Hall et al. 2005; Lemke et al. 2010; Stockdale, Cassell, & Ford, 2018) and 
decreases in employability status (Geller et al. 2002; Tambor et al. 2002). Indeed, in a study of 
9 focus groups discussing the implications of genetic research, the topic of discrimination 
relating to employment and insurance came up in every group (Bates et al. 2005). This study 
also found that African Americans believe racial discrimination may arise from genetic 
research more than their white counterparts - a finding that has been replicated in other 
studies (Goldenberg et al. 2011; Peters, Rose, & Armstrong, 2004; Suther & Kiros, 2009; 
Middleton et al. 2018; Zimmerman et al. 2006). 
 
 
1.7.2.3 Concern: data sharing & security  
1.7.2.3.1  Access by research institutions 
More generally, the public have also expressed fears about sharing their medical data for 
research purposes that includes sharing across different institutions and outside of their 
country of residence (Majumder, Cook-Deegan & McGuire, 2016). Only 24% of UK participants 
indicated they would trust medical research institutions with their data (Open Data Institute, 
2018).  Indeed, one study found that whilst 96% of participants supported the sharing of data 
for a patient’s care, this decreased to 74% when the purpose was medical research (New 
Economics Foundation, 2010).  
 
The public worry that research using their genetic data could damage their medical privacy 
(Anderlik & Rothstein, 2001; Gill & Richards, 1998; Kaufman et al. 2009), result in the copying 
and planting of their DNA at a crime scene, or the government and/or friends and family 
finding out something that the individual did not opt to disclose (Middleton, 2017).  
 
1.7.2.3.2     Security of data in the NHS 
However, it is not just research institutions that prompt anxiety from the public. Whilst trust in 
the NHS is high (Healthwatch England, 2018; Understanding Patient Data, 2018), research 
indicates the existence of a ‘gulf’ between how the public think the NHS could use their data 
and reality (New Economics Foundation, 2010). In fact, only 20% feel well-informed about 
 30 
how their genomic data could be used (Healthwatch England, 2018), and one study found 
71.3% of participants are doubtful that the NHS can assure full security of electronic health 
records (Stockdale, Cassell, & Ford, 2018).  
  
1.7.1.4 Concern: genomic data is ‘different’  
A further barrier to genetic data sharing is ‘genetic exceptionalism’ – the perception that the 
genome is unique and distinct from other types of data, e.g. mental or sexual health data 
(Davies, 2017).  Indeed, as discussed, there are some aspects of genetic data that make it 
different to other types of data. For example, genetic data challenges traditional ideas of 
consent and therefore people are concerned about implications for family members when 
having a genetic test themselves. However, there are some other concerns that are perhaps less 
realistic, such as the idea that our current knowledge of genetics is enough for it to be used in 
ways to edit characteristics of unborn babies, e.g. having a scheme in which parents can choose 
the intelligence of their unborn child.  This could be linked to the misguided tendency to see 
genetic data as highly predictive and definitive, i.e. genetic determinism (Clayton, 2003; See 
section 1.6.2.4), or the related notion that genetic technology and using genetic data in 
healthcare is ‘playing God’ (Bates et al. 2005; Henneman, Timmermans, & Wal, 2006; Lassen & 
Jamison, 2006; Tambor et al. 2002).  Regardless of its cause, ‘genetic exceptionalism’ can cause 
patients to have increased feelings of vulnerability and anxiety around sharing their genetic 
data which, whilst it is important for the public to have an awareness of the nature of genetic 
data, can lead to a high missed opportunity cost (Davies, 2017).  
 
1.7.1.5 Are these concerns legitimate?  
Concerns that are held by the public need to be examined and evaluated. The extent to which 
the concern is reasonable has different implications for genomic medicine. If a concern is more 
legitimate, we may have to consider changes to practice, but if the concern is more due to a 
misunderstanding, we may need to reassure the public through increased communication of 
the reality of the situation. However, it is important to recognise that whilst legally a concern 
may not be ‘legitimate’, there is always the possibility of accidental or illegal data access 
and/or leakage. Therefore, we can provide the public with the necessary information but 
should also ensure this does not lure them into a false sense of security, i.e. we should provide 
the information in an unbiased, accurate and balanced way.   
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For example, the most recent code on genetic testing and insurance states that insurers are 
only permitted to request a genetic test result if the test is both for Huntington’s disease and 
for life insurance equalling above £500,000 per person (Government and the Association of 
British Insurers, 2018). This rule will be reviewed every 3 years and thus is subject to change. 
Presently, however, we could be providing the public with this information when they raise 
concerns about discrimination from insurers.  Similarly, due to the current lack of genetic 
testing occurring in workplaces and the limited predictive value of genetic tests, specific 
legislation against genetic discrimination from employers has not yet been created (UK 
Parliament, 2009). Instead, employees are protected by broader laws such as the Disability 
Discrimination Act (1995), the Human Tissue Act (2004) and the Human Rights Act (1998) and 
the situation is monitored closely by the UK Government. This information could also be 
provided to the public when they raise concerns about genetic discrimination.   
 
However, Selita (2019) noted that there have been some suggestions as to how to use genetic 
information in the selection of employees. For example, the US military have been 
recommended to look at the genetic profiles of potential military personnel to establish their 
genetic ability to tolerate stressful situations (The MITRE Corporation, 2010).  Therefore, 
whilst current practice does not include the use of genetic information for employment 
purposes, the future is uncertain. Further, Selita (2019) recognised that the current trend of 
diminishing social provisions, coupled with ever-present health difficulties, means that an 
increasing portion of the public are turning to private insurance. Also, mental health illnesses 
are often undiagnosed (Mental Health Foundation, 2016); genetic information offers an 
instrumental tool to establish an individual’s risk for health problems and consequently 
determine their insurance premium. Overall, the growing popularity of private insurance and 
the invaluable nature of genetic information to insurance companies arguably presents a case 
for changes to the rules surrounding access to genetic information.  
 
 
Further, regarding worries about the security of data in the NHS, the public may be assured to 
know that genetic data, due to its sensitivity, falls under ‘special category data’ and thus gets 
extra protection (Information Commissioner’s Office, 2019). For example, NHS staff are 
allocated ‘smartcards’ to access data. The amount of data they can access is automatically 
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adjusted based on their job, and they are only allowed access if they have good reason, e.g. to 
provide care (NHS England, 2011). Cyber security is recognised as an ongoing risk and thus 
managed at board level within the NHS - they have a Cyber Security Programme. Further, the 
NHS must store and secure genetic data in line with the rules of the Data Protection Act (NHS 
England, 2018c), which includes a legal obligation to apply suitable measures to protect such 
data (Data Protection Act, 2018), and the EU General Data Protection Regulation (GDPR). In 
fact, GDPR was the first legal framework to explicitly identify the category of genetic data (PHG 
Foundation, 2019).  
 
However, having laws in place and a Government that oversees the situation by no means 
cancels out all serious concerns. There is still the possibility of negligence in data storage, 
accidental leaking of data, the illegal use of or access to information, or indeed the use of 
genetic information in specific circumstances, such as the recent use of a genealogy website to 
compare a suspect’s DNA to the genetic profiles of the website’s customers (Solon, 2018). 
Therefore, whilst we can increase communication of the laws and legislation surrounding 
genetic data, we should not use this information to ignore or diminish the public’s concerns; 
there is a real possibility that some could still occur. All in all, the public should be provided 
with accurate and unbiased information regarding how data is stored and the way in which it 
is protected. Importantly, their decision as to whether or not to donate their genetic data is 
entirely their own and we should be using this information to inform, not manipulate, their 
choice.  
 
With regards to concerns about commercial companies, if an individual gives consent to the 
use of their genetic data to research as well as for diagnostic testing within the NHS, this 
includes access by commercial partners. The commercial value of genomic data has the 
potential to bring large benefits to the NHS (UK Parliament, 2018) and collaborations with 
industry are required so that the NHS have sufficient funds to sequence, interpret, and store 
genetic data as well as develop new medicines (Life Sciences Industrial Strategy Board, 2017). 
For example, the NHS collaborated with the commercial technology provider Illumina during 
the successful 100,000 Genomes Project (Genomics England, 2016). Despite the necessity of 
commercial collaborations, this is a more legitimate concern because commercial companies 
are actually allowed access to people’s genetic data. Perhaps changes to policy, such as  a rule 
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whereby we must inform the public exactly which commercial organisations are allowed 
access, could be made.  
 
1.7.1.6 Benefit: healthcare 
Despite the aforementioned concerns and the lack of genetic knowledge shown in some studies 
(Chapman et al. 2019; Haga et al. 2013; Lanie et al. 2004; Richards, 2016; Walter et al. 2004) 
there is widespread public confidence that genomics will confer many benefits to healthcare 
(Hahn et al. 2010; Horrow et al. 2019; Health Research Authority, 2018; Wellcome Trust, 
2016). As the perceived usefulness of genetic testing increases, so does the likelihood that it 
will receive support (Gaskell et al. 2000). One study found that 79.9% of participants cited 
improving their health as an important motivator to take part in genetic testing (Gollust et al. 
2012). In fact, an Australian study found participants attributed higher importance to the 
maximisation of healthcare benefits from genomics than gaining specific consent for use of 
their genetic data in new studies (Critchley, Nicol, & McWhirter, 2017).  The following section 
will explore areas within genomics that inspire public enthusiasm and excitement.   
 
1.7.1.6.1 Impact on treatment 
Research shows the public are optimistic about the possibility of developing both improved 
and new treatments as a result of genomic medicine. For example, public dialogue workshops 
found the majority of participants were excited about the possibility of better NHS treatments 
(Health Research Authority, 2018), and one of the most cited benefits in another study was the 
possibility of new treatments (Hahn et al. 2010). Indeed, 44% of participants who had 
originally opposed commercial companies having access to genetic data would reverse that 
decision if it meant the development of novel treatments would not take place (Wellcome 
Trust, 2016). Further, one study found that 90.7% of participants displayed confidence that 
genomics will help doctors choose the best treatment for patients (Horrow et al. 2019) 
 
1.7.1.6.2 Diagnoses  
Studies also show support for genomic medicine because it could help patients get an accurate 
diagnosis. For example, a study exploring opinion of technological interventions found that 
84% of participants supported genetic screening tests for cystic fibrosis - the most supported 
intervention across the entire study (Calnan, Montaner, & Horne 2005). Other research 
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discovered that 91% of participants endorsed a statement that indicated a high likelihood that 
genomic medicine will help doctors diagnose rare diseases (Horrow et al. 2019). 
 
1.7.1.6.3 Knowledge of genetic risk & prevention 
The public also hold high hopes that genomic medicine will encourage preventative measures 
by providing information about genetic risk. Indeed, one study found that those who think that 
knowing the genetics of disease will encourage healthier lifestyles in those who are at genetic 
risk are less likely to be opposed to genomic medicine (Henneman, Timmermans, & Wal, 
2006). The same study found that, whilst most participants originally wanted to remain in the 
dark about their genetic disease risk, once the possibility that the disease in question was 
preventable, interest increased to over 50% of participants. Similarly, another study found 
78.4% of participants were motivated to take part in genetic testing because they wanted to 
know which diseases they were at risk for (Gollust et al. 2012), and qualitative research has 
found that attitudes to genomic medicine are heavily informed by the perceived utility of the 
genomic information (Nicholls et al. 2013). 
 
However, whilst some studies indicate that genetic test results improve and/or increase users’ 
healthy behaviours (Gordon et al. 2012; Kaufman et al. 2012; Roberts, Christensen & Green, 
2011) other studies show that users of genetic tests make no changes to their behaviour (Bloss 
et al. 2010; Bloss et al. 2013; Hollands et al. 2016). Research exploring the impact of genetic 
results on anxiety also shows mixed findings. Some researchers suggest that genetic results 
may decrease anxiety in users (Hilgart, Coles, & Iredale, 2012), whilst others suggest results 
have no effect on anxiety (Bloss et al. 2010; McBride, Wade & Kaphingst, 2010; Roberts, 
Christensen & Green, 2011) or may increase anxiety (Samuel, Jordens, & Kerridge, 2010). 
Given these mixed findings, the perceived importance of the utility of genetic tests (Nicholls et 
al. 2013) is brought into question.  
 
1.7.1.7 Benefit: the greater good 
1.7.1.7.1 Societal benefit 
More broadly, a key condition for public acceptance of sharing patient data and using it beyond 
individual care is that it will confer some benefit to society (Asthma UK, 2018; Wellcome Trust, 
2016; Tully et al. 2018; Understanding Patient Data, 2018). Indeed, qualitative work found the 
majority of participants comment on the cruciality of genetic research to offer some societal 
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benefit (Stolt et al. 2002). In addition, the public appear keen to participate in research, with 
80% of participants stating they would want their clinician to inform them about medical 
research they could get involved in (Ipsos MORI, 2011). In fact, a systematic review found that 
a main component of a trustworthy, supported organisation was the public’s perception that 
they had the ‘right motivations’, i.e. public benefit (Stockdale, Cassell, & Ford, 2018). Research 
shows there may be an element of social organisation to individual decision-making: those 
who take part in medical research do so to demonstrate their connection with others and to 
confer a benefit to the public good (Dixon-Woods & Tarrant, 2009). 
 
1.7.1.7.2  Scientific advancement 
Finally, qualitative research indicates that agreeing to share genomic data is encouraged by the 
idea that it may benefit scientific and medical research (Thiebes, Lyytinen & Sunyaev, 2017). In 
support of this, 94.3% of participants trust that genomic medicine will help scientists discover 
facts about genes (Gollust et al. 2012) and 94.6% of participants believe it will help to answer 
difficult questions about disease in the next 5 years (Horrow et al. 2019). Overall, it is clear that 
the ‘double-edged sword’ description of genomics (Michie et al. 1995) still stands today. Now, 
an interesting and important avenue to explore is the factors that feed into public backing of 
genomics. To this end, the following section will explore the role of genetic knowledge.  
 
1.8 Does knowledge of genetics link to acceptance of 
genomic medicine? 
 
1.8.1  Deficit model – in support of a positive relationship 
between knowledge & acceptance 
The assumption that a lack of acceptance of genomics is a result of a misunderstanding of 
genetics is based on the ‘deficit model’, that assumes scepticism and fear towards science and 
technology is due to a deficiency in public scientific understanding (Sturgis & Allum, 2004). 
There are scientific studies that provide support for this model (Hayes & Tariq, 2000; Morren 
et al. 2007). For example, one study found that one of the greatest predictors of the public’s 
perceptions of benefits from biotechnology, which included genetic testing, was the degree to 
which an individual was informed about biotechnology (Pardo, Midden, & Miller, 2002).  
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With regards to genetics more specifically, a large UK study by the Human Genetics 
Commission (2001) found participants with low levels of genetic knowledge were least likely 
to acknowledge that developments in genetics may bring cures for disease. These participants 
were also the most likely to perceive genetic research as interfering with nature and thus as 
unethical. Further, an analysis of survey results from UK adults found those with higher 
scientific knowledge displayed more optimism about medical genetics and more enthusiasm 
about genetic testing (Allum et al. 2014) and, similarly, a study by Chapman et al. (2019) found 
a weak but positive relationship between participants’ knowledge of genetics and their 
readiness to take a genetic test for medical reasons. A recent experimental study, which 
explored the effect of an in-class lecture in clinical genetics on undergraduates’ attitudes 
towards genetic testing, also provided support for the deficit model (McClintock, 2019). The 
lecture included information on the limitations of clinical genetic testing, the types and 
classifications of genetic tests, and the benefits of prenatal testing. Participants who were 
exposed to the lecture displayed increased positive attitudes towards genetic testing compared 
to those who did not receive the lecture.  
 
1.8.2 Evidence against a relationship between knowledge and 
acceptance 
1.8.2.1      No evidence for a relationship 
However, contradictory to the deficit model and the above studies, there is evidence of a null 
relationship between scientific knowledge and positive attitudes towards science. For example, 
Gottweis (2002) suggests that low levels of acceptance of gene therapy are caused not by a lack 
of knowledge but a lack of trust in scientists and technology. Further, an analysis of 1,308 
survey responses from Dutch participants found genetic knowledge was not significantly 
associated with the participants’ status of being either an ‘opponent’ or a ‘supporter’ of genetic 
tests (Henneman, Timmermans, & Wal, 2006). Rather, familiarity with a genetic disease was 
associated with a decreased likelihood of being opposed to genetic testing. Additionally, 
contrary to McClintock’s (2019) experiment, another experimental UK study found the 
provision of a 10-minute scientific documentary about genomics had no impact on 
participants’ overall attitude to genetic science and databanks (Sturgis, Brunton-Smith, & Fife-
Schaw, 2010). 
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1.8.2.2  Evidence for a negative relationship 
Finally, there is also some evidence of a negative relationship - one study discovered 
individuals who were most knowledgeable about genes were also the most concerned that 
genetic tests will not improve people’s quality of life and may lead to eugenics, whilst those 
least knowledgeable were most unsure of how they felt (Jallinjoa & Aro, 2000). Further, in 
morally controversial fields of research, which arguably includes genetics, more-
knowledgeable individuals have been found to hold stronger opposing views to research than 
those who were less informed (Evans & Durant, 1995).  
 
1.9    The present study   
Overall, the relationship between knowledge and attitudes is not well-defined. The present 
study aimed to investigate the hypothesis that fear towards genomic medicine is due to a lack 
of knowledge. The study explored genetic knowledge in three different ways: 1) participants’ 
biological knowledge of genetics, 2) their clinical knowledge of genomic medicine, and 3) their 
perception of their genetic knowledge.  
In addition, given the controversial nature of genomic medicine, I conducted two focus groups 
to explore public concerns, expectations, and opinion of the use of genetics in healthcare. To 
the best of my knowledge, this was one of the first focus groups gathering public opinion about 
the most recent NHS plans for genomic medicine. This was an exploratory study with no 
specific hypotheses.  
1.9.1 Why the UK public? 
1.9.1.1 Importance of research into the UK  
Differing opinions on the topic of genetics may arise as a result of cultural sensitivities, 
historical influences (Gaskell et al., 1999) or country of residence (Gaskell et al. 2000), e.g. UK 
participants have shown greater support for genomic research than their Australian and 
American counterparts (Middleton et al. 2018). Therefore, the participants in my study may 
hold views that are not present within other cohorts. Further, it is important to specifically 
explore the views of the UK public given that the UK is the first country in the world to bring 
genomics into a mainstream healthcare system (Davies, 2017) and, in addition, has a 
healthcare system that differs vastly from other countries such as the US, Japan and Australia 
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(Duncan & Jowit, 2018). The fast pace of genomics in the UK may foster thoughts and opinions 
that are exclusive to those who reside in this country. 
 
1.9.1.2 Importance of research into the public 
The development of genome policies using only the opinion of experts limits the possibility of 
success as they would be unlikely to generate satisfaction in all stakeholders (Haga & Willard, 
2006). Also, attempts to understand public attitude towards genomics could uncover sources 
of scepticism and gaps in knowledge, that in turn could be used to focus communication efforts 
(Henneman et al. 2013). On a more practical level, biobanks depend upon members of the 
public to donate samples and information (Samuel & Farside, 2018) and members of the public 
pay for research and are prospective users of the resulting products (Bates et al. 2005). 
Overall, the controversial nature of genetics means the involvement of the public is crucial to 
increase accountability in the decision-making process (Samuel & Farsides, 2018). 
 
 
1.9.2    How to address the research question? Use of quantitative 
& qualitative methods 
This project used a mixed methods design. Use of a quantitative design allowed for a reliable, 
generalisable and powerful conclusion. Contrastingly, whilst the qualitative results are not 
generalisable to the larger UK population, they allow for a deeper insight and may uncover 
complexities that had not been considered previously. A mixed-methods approach can enable 
the collection of different and sometimes opposing views (Greene, 2007). The combination of 
both studies’ strengths is vital if we are to inform changes to practice based upon a full 
understanding of public perception of genetics in healthcare.  
 
1.10     Chapter summary  
In this chapter, I have outlined the current state of genomic medicine, as well as its history and 
hopes for the future. I discussed the controversial nature of genetic data, the public’s concerns 
and expectations, and gave an overview of the evidence for and against the deficit model. This 
led us to one of my research questions: does knowledge of genetics predict acceptance of 
genomic medicine? The importance of research into public opinion directed us to my second 
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research question: what concerns and expectations do the UK public hold about genomic 










































Chapter 2: Quantitative study – Does 
knowledge of genetics predict 
acceptance of genomic medicine? 
 
2.1  Introduction 
Genomic medicine is becoming increasingly relevant and thus important for all members of the 
UK public. As the Chief Medical Officer acknowledged, the success of genomic medicine 
depends on the establishment of public trust (Davies, 2017). The question remains, however, 
as to the best methods of communication to achieve this aim. It is unclear whether attempts to 
improve genomic literacy and understanding will improve public acceptance of genomic 
medicine. Understanding and characterising the relationship between knowledge and 
acceptance of genomic medicine will help to guide educational efforts and resources. In turn, 
this will maximise the probability that the UK public will engage in and be supportive of the 
use of genetic data in healthcare.  
 
On the one hand, some research indicates that such an educational undertaking will improve 
public acceptance. The deficit model suggests that the endorsement of a scientific belief or 
domain is intrinsically linked to how much scientific knowledge one holds (Sturgis & Allum, 
2004). In other words, the more science you know, the more comfortable you feel with a 
particular scientific area. As mentioned in 1.8.2, there is literature to support this claim within 
the domain of genetics (Allum et al. 2014; Human Genetics Consortium, 2001; Chapman et al. 
2019; Pardo, Midden, & Miller, 2002).  
 
On the other hand, other research indicates that attempts to increase public understanding of 
genetics may have no impact on public acceptance (Henneman, Timmermans, & Wal, 2006; 
Sturgis, Brunton-Smith, & Fife-Schaw, 2010) or indeed may have the opposite intended effect 
(Jallinoja & Aro, 2002). These studies suggest that other variables are far more important in 
determining an individual’s level of acceptance towards genetics, and thus resources may be 
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better spent elsewhere. These other variables include the level of trust in scientists (Gottweis, 
2002), familiarity with a genetic disease and belief in the personal benefits of genetic testing 
(Henneman, Timmermans, & Wal, 2006), and how controversial the scientific application is 
(Bak, 2001).  
 
Overall, we are left with scientific evidence to both support and counter the deficit model, and 
the nature of the relationship between genetic knowledge and acceptance of genomic medicine 
remains uncertain. Importantly, however, a review of studies between 1993 and 2008 into the 
deficit model found that the strength of the relationship depended on the specific type of 
scientific knowledge studied (Allum et al. 2008). For example, the relationship between 
general scientific knowledge and positive attitudes to genetically modified (GM) food was 
almost non-existent. However, biological/genetic knowledge was a strong predictor of positive 
attitudes to GM foods. Crucially, the overall relationship between biological/genetic knowledge 
and positive attitudes to genetic medicine was non-significant.  Allum et al. (2008) concluded 
that future research should focus on specific aspects of scientific knowledge, rather than using 
a more general measure of scientific knowledge. The field of genetics has changed vastly since 
Allum et al’s study in 2008 (see Figure 1). Therefore, my research is crucial if we are to identify 
the relationship between knowledge and acceptance as it exists within the UK public today.   
 
Indeed, whilst some aforementioned studies specifically explored genetics (Allum et al. 2014; 
Chapman et al. 2019; Human Genetics Consortium, 2001; Jallinjoa & Aro, 2000; Sturgis, 
Brunton-Smith, & Fife-Schaw, 2010), other research has explored a multitude of domains. This 
includes public opinion on health data (Asthma UK, 2018; Wellcome Trust, 2016), personal 
data (Open Data Institute, 2018), medical data (Majumder, Cook-Deegan & McGuire, 2016) 
electronic health records (Stockdale Cassell, & Ford, 2018), biotechnology (Pardo et al. 2002) 
and gene therapy (Gottweis, 2002). Thus, there is a need for more research that specifically 
explores genetic knowledge and how that links with acceptance of the use of genetic data in 
healthcare.  
 
The present study sought to specifically test participants’ biological knowledge of genetics, 
defined by their knowledge of genes and how they work in the body, their clinical knowledge 
of genetics in healthcare, defined by their awareness of the current situation regarding the 
genomic medicine service in the UK, and their perception of their genetic knowledge. I also 
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measured participants’ level of acceptance of the use of genetic data in UK healthcare. This 
included questions that were only relevant to the state of genomics in the UK (see 2.2.1.6). I 
aimed to test the hypothesis that fear towards genomic medicine is due to a lack of 
understanding of biological and/or clinical knowledge of genetics. I added perception of 
genetic knowledge as an exploratory measure. This study is novel because, to my knowledge, 
no previous studies have made this distinction between biological and clinical knowledge in 
order to explore their relationship with public acceptance of genomic medicine. Further, this 
study specifically looked at the UK public. Whilst some previous research into public 
knowledge of and acceptability towards genetics has been conducted in the UK (Calnan, 
Montaner & Horne, 2005; Castle-Clarke, 2018; Healthwatch England, 2018; Middleton, 2018), a 
large amount of research is focused in the US (Christensen et al. 2010; Condit et al. 2004; 
Kaufman et al. 2009; Kessler, Collier, & Halbert, 2007; Majumder, Cook-Deegan, McGuire, 2016; 
McClintock, 2019) or in Europe more broadly (Gaskell et al. 2001; Henneman et al. 2013; 
Pardo, Midden & Miller, 2002). Given the unique position of the UK as the worldwide leader of 
genomic medicine, the exploration of the relationship between knowledge and acceptance in 
members of the UK public is particularly pressing. 
 
2.2  Method 
This study was approved by the University of Bristol School of Psychological Science Research 
Ethics Committee on the 12th October 2018 (ethical approval code: 75841; see Appendix 1). 
The overall process of developing the survey included the following key steps: development, 
distribution, analysis of the first wave data and comparison with UK census data, targeted re-
distribution, and final statistical analysis. The methodological  
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steps in this study have been summarised in Figure 3 below. The following sections will 
elaborate upon each step in this overall process. 
 
Figure 3 Overall steps of the development of the survey exploring people’s biological knowledge of 
genetics, their clinical knowledge of genetics in healthcare, their perception of their knowledge,  
and their acceptance of genomic medicine. 
 
2.2.1  Development of the survey instrument  
The survey consisted of 6 sections: (1) Demographic information; (2) Experience with genetic 
testing, (3) Biological knowledge of genetics; (4) Clinical knowledge of the use of genetics in 
healthcare; (5) Perception of genetic knowledge; (6) Acceptance of the use of genetic data in 
healthcare. 
 
The final instrument included a mix of newly constructed questions, questions that had been 
developed upon discussion with a genetic counsellor, and questions adapted from previous 
instruments. These instruments included: the Wellcome Trust Monitors (2012; 2016); the 
Public Understanding and Attitudes towards Genetics and Genomics survey (PUGGS; Carver et 
al. 2017); the International Genetic Literacy and Attitudes Survey (iGLAS; Chapman et al. 
2017); questions from a Genes and Behaviour course assessment used at the University of 
Bristol (Haworth, 2018); and Your DNA, Your Say, a survey designed by The Society for Ethics 
Research Group at the Wellcome Genome Campus (Middleton, 2017). I chose questions from 
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these sources to test the four core topics: biological knowledge, clinical knowledge, perception 
of knowledge, and acceptance of genomic medicine. For further details regarding the exact 
source of each question, refer to Appendix 2.  
 
2.2.1.1  Demographic information 
We asked participants for general demographic information, i.e. age, gender, ethnicity, 
education, as well as information specifically relevant for this study, such as if participants 
worked for the NHS, when they were last taught about genetics, whether they come across 
genetics in the workplace, and finally whether they have any children. I added these additional 
demographic questions as I acknowledged that these factors may influence participants’ 
knowledge of genetics and/or acceptance of genetics in healthcare and wanted to be able to 
control for them.  
 
2.2.1.2  Experience with genetic testing 
In addition to the above, I recognised that an additional confounding variable could be 
participants’ experience with genetic testing. Indeed, research indicates a disconnect between 
the general public’s and patients’ perceived benefits of genomic medicine (Critchley, Nicol, & 
McWhirter, 2017). Thus, participants were asked questions such as (for all questions, see 
Appendix 2):  
 
Have you or anyone close to you ever had a genetic test done by a doctor? 
 
2.2.1.3 Measuring biological knowledge of genetics 
We wanted to measure participants’ level of knowledge regarding the biology of genes and the 
mechanisms of genetic influences. The overall process of the development of this measure is 
summarised in Figure 4. The following sections will elaborate on this process. 
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  * = Some/all question/s adapted format and/or content adapted for the current survey. 
Figure 4 Steps in the development process  of the biological knowledge of genetics measure. 
 
2.2.1.3.1  Step 1: Initial instrument 
An initial assessment was developed that included questions from the 2012 and 2016 
Wellcome Trust Monitors and newly constructed questions. For example, I used a true/false 
question from the Wellcome Trust Monitor (2016) that tested participants’ knowledge of the 
genetic influences from biological parents: 
 
It is the mother’s genes that determine the sex of the child 
 
A question from the Wellcome Trust Monitor (2012) paper tested participant’s knowledge of 
genetic probability:  
 
A doctor tells a couple that they’ve got a one in four chance of having a child with genetic 
disease... 
• ...if their first three children are healthy, the fourth will have the illness  
• ...if their first child has the illness, the next three will not 
• ...each of the couple's children will have the same risk of suffering from the illness 
• ...if they have only three children, none will have the illness 
 
The above question also motivated the development of two newly constructed questions, both 



































the relative influences of genetics and the environment, I developed, piloted, and included the 
following question: 
 
A patient is told that the results of their genetic test indicate they are at increased risk of a 
particular disease. Consequently, they decide to engage in healthier behaviours, such as exercising 
regularly and eating a more balanced diet.  
• ...their increase in healthier behaviour will have no effect on their likelihood of developing 
the disease, because their genetic test indicates they will definitely develop the disease at 
some point 
• ...their increase in healthier behaviour will definitely decrease their likelihood of 
developing the disease, because the effect of the environment will always override the 
influence of their genes 
• ...their increase in healthier behaviour may lead to a decrease in their likelihood of 
developing the disease, because the way their genes work can be altered by their 
environment 
 
Additional newly constructed questions were developed through an exploration of common 
misunderstandings of genetics (Christensen et al. 2010; Dar-Nimrod & Heine, 2011; Klitzman, 
2010). For example, inclusion of the false statement, ‘Genes are always more important for how 
you look than how you behave’, in the question ‘Which statement is TRUE’, tested participants’ 
level of genetically deterministic beliefs and how they distinguish between physical and 
behavioural traits.  
 
2.2.1.3.2  Step 2: First pilot study 
We piloted the initial version of this measure and recruited 26 participants via email and social 
media (Female =15, Mean age =32yrs). Results indicated that overall scores displayed a ceiling 
effect and were skewed towards the 100% correct mark. For further details, see Appendix 3.1.  
 
2.2.1.3.3 Step 3: Adjustment & addition of questions 
The findings from the pilot indicated that, in order to eliminate the ceiling effect and the 
skewed nature of the data, I needed to increase the difficulty of the questions. Indeed, a large 
majority of the questions gave only two options for the answer (True or False), meaning that 
participants had a 50% chance of guessing the correct answer. Therefore, I rearranged the 
structure of the questions in order to generate 2+ possible answers. For example:  
 
Which of the following is TRUE: 
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• It is the mother’s genes that determine the sex of the child 
• If there is no family history of disease, then there is no chance of a newborn baby having 
said disease 
• Humans share approximately 99% of their DNA with each other 
 
To increase the difficulty further, I incorporated questions adapted from multiple additional 
sources. These included: Public Understanding and Attitudes towards Genetics and Genomics 
survey (PUGGS; Carver et al. 2017); University of Bristol Genes and Behaviour course 
assessment (Haworth, 2018); and the International Genetic Literacy and Attitudes Survey 
(iGLAS; Chapman et al. 2017).  The following is an example of a question from iGLAS (Chapman 
et al. 2017), which tests participants’ knowledge of the role genes in the human body: 
 
What is the main function of all genes? 
• Storing information for protein synthesis 
• To provide energy to the cell 
• To clear out waste from the cell 
• To repair damage to the cell 
 
Finally, through my collaboration with the NHS West of England Genomic Medicine Centre, I 
organised a meeting with a genetic counsellor. We discussed the most common unknowns in 
the biology of genetics and their influence on healthcare, and two true statements were 
consequently incorporated into questions: ‘Your genetic make-up can influence the way that you 
respond to medical interventions’ and ‘Cancer can be caused by both inherited genetic mutations 
or mutations that are acquired throughout the lifetime’.  
 
2.2.1.3.4  Step 4: Second pilot study 
A second pilot study recruited 32 participants through social media and email (Female =25, 
Mean age =34yrs). Results indicated a normal distribution of overall scores with an acceptable 
level of skewness (see Appendix 3.2 for results).  Therefore, the revised version of this section 
was considered suitable for testing. 
 
 
2.2.1.4 Measuring clinical knowledge of the use of genetic data in 
healthcare 
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The second section of the survey was designed to assess participants’ knowledge of the current 
situation regarding the use of genetics in healthcare, i.e. their clinical knowledge. Figure 5 
below indicates the overall process of this measure’s development, and the following sections 

















* = Some/all question/s format and/or content adapted for the current survey. 
Figure 5  Steps in the development process  of the clinical knowledge of genetics measure. 
 
2.2.1.5.1  Step 1: Instrument development 
Newly constructed (false) statements were created by the lead researcher and based upon 
common misunderstandings and misconceptions of genetics in healthcare. For example, 
research indicates the public hold unrealistic and exaggerated expectations of genomics (Evans 
et al. 2011). Thus, the following false statements were developed to test such inflated beliefs: 
 
Using an individuals’ genetic code, we are currently able to predict whether an individual will 
develop every single disease known to the medical community 
 


































Other true/false questions were formulated through examination of the information on the 
websites of Genomics England (2018) and NHS England: Improving Outcomes Through 
Personalised Medicine (2016) and NHS: Screening tests in pregnancy (2018c). For example:  
 
Through a number of genetic testing techniques, it is possible to detect genetic abnormalities in 
an unborn child 
 
In addition, the recent ‘Patient ABC versus St George’s Healthcare Trust’ case (Dyer, 2015), 
which challenges conventional ideas of medical confidentiality, motivated a question regarding 
legal responsibility and patient privacy. The question developed was as follows: 
 
It is against the law for a doctor to not disclose a patient’s genetic test results to their close 
relatives as, given their genetic relatedness, the results may also concern them 
 
Another true/false question was added after discussions with a genetic counsellor revealed 
that many people are unaware of the exact role of a genetic counsellor: 
 
A patient will only speak with a genetic counsellor if their genetic test result indicates they have a 
genetic predisposition to a disease 
 
Finally, inclusion of a question adapted from the Wellcome Trust Monitor (2016), (How much 
have you read or heard about genetic tests that predict the likelihood that a person will develop 
certain genetically influenced diseases or conditions, such as heart disease, cancer and 
Alzheimer's?), motivated yes/no questions that explored participants’ self-reported awareness 
of specific phrases and projects. For example:  
 
Have you heard of the 100,000 Genomes Project? 
 
Have you heard of the phrase ‘personalised medicine?’ 
 
2.2.1.5.2  Step 2: Piloting  
This version of the measure was piloted, and participants recruited via social media and email 
(Female =25, Mean age =34yrs). Results revealed a normal distribution of overall scores with 
an acceptable level of skewness (see Appendix 3.3 for further detail). Thus, the measure was 
deemed acceptable to include in the final survey. 
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2.2.1.5 Measuring participants’ perception of genetic knowledge 
In addition to testing participants’ biological knowledge of genetics, I also included questions 
to measure participants’ perception of their genetic knowledge. This was an exploratory 
measure, included in order to examine whether the public accurately rate their knowledge of 
genetics, and included a total of 4 questions. For example, I used a question from the Wellcome 
Trust Monitor (2012) to explore participants self-reported understanding of the ethical issues 
within genetic research, from ‘Very good’ to ‘Have not heard the term’. Another question was 
also from the Wellcome Trust Monitor (2012): 
 
When you hear the term DNA, how would you rate your understanding of what the term means? 
 
In addition, I incorporated similar questions from the 2016 and 2013 version of the Wellcome 
Trust Monitors that asked participants to rate their understanding of the terms ‘genetically 
modified’ and ‘human genome’, respectively.  
 
 
2.2.1.6  Measuring acceptance of genetics in healthcare 
The final measure in the survey was designed to explore how accepting participants feel 
towards the use of genetic data in healthcare. Figure 6 below summarises the development 
process, and the following sections will elaborate upon each step of the process. 
* = Some/all question/s format and/or content adapted for the current survey 
































First, participants were given a brief overview of the current situation regarding the use of 
genetic data in healthcare in the UK, adapted from information from the websites of NHS 
England (2018a) and Genomics England (2019). This was to ensure that participants answered 
questions on an informed basis. For example, ‘Overall, the aim is to create a new genetic 
medicine service for the NHS … patients may be offered a diagnosis where there wasn't one before 
or may be able to make more informed decisions regarding their treatment.’  
 
Next, questions were adapted from the Wellcome Trust Monitors (2012; 2016); iGLAS 
(Chapman et al. 2017); PUGGS (Carver et al. 2017); and Your DNA, Your Say (Middleton, 2017). 
For example, to test participants’ trust in the NHS, the following question was adapted from 
Chapman et al. (2017) and measured on a 6-point scale from ‘Strongly agree’ to ‘Strongly 
disagree’:  
 
I do not trust the healthcare system in the UK because it might misuse genetic data obtained from 
patients 
 
Additional questions were incorporated following research into common concerns about 
genetics in healthcare (Haddow et al. 2007; Nowlan, 2002; Zaidi, 2018). For example, a news 
article entitled ‘Why a DNA data breach is much worse than a credit card leak’ (Chen, 2018) 
motivated the development of the following question, again to explore whether the present 
participants hold beliefs that are consistent with genetic exceptionalism (Davies, 2017):  
 
I would be more concerned about my genetic data being leaked than my credit card information 
 
Finally, a question was developed following attendance at Professor Robert Plomin’s annual 
lecture at the University of Bristol - Blueprint: How DNA Makes Us Who We Are (Plomin, 
2018). In this lecture, Plomin discussed the benefits of knowing your genetic information, and 
the notion that ‘knowledge is power’: 
 
 Finally, imagine yourself in the following scenario. You have an opportunity to have a genetic test 
that may reveal that you are going to develop a condition that currently does not have any 
medical treatment options. Which statement do you agree with most?    
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• Knowledge is power: I would rather have the genetic test, so that I can prepare financially, 
emotionally, and practically if I am found to have a genetic variant that will lead to an 
(currently) incurable disease 
• Ignorance is bliss: I would rather not have a genetic test, because if I am found to have a 
genetic variant that will lead to an (currently) incurable disease I would worry about it 
too much to be able to carry on enjoying my life to the full 
• I’m not sure 
 
We did not pilot the acceptance measure as I expected a range of opinions and there were no 
right or wrong answers. Therefore, it was unlikely to result in a ceiling (or floor) effect in the 
same way as the knowledge measures of the survey. 
 
2.2.1.7   Additional questions 
Six questions did not explicitly explore acceptance of genomic medicine but were included to 
form part of an additional exploratory analysis of public attitude towards genomic medicine. 
For example, motivated by the aforementioned legal case (Dyer, 2015), the following question 
was designed to explore participants’ attitudes towards the level of responsibility of 
genetically related family members and again measured on a 6-point scale of agreement:  
 
Family members share many genetic traits and may have the same genetic 
abnormalities associated with disease. Therefore, all immediate family members must give 
consent before an individual in that family gets a genetic test for medical reasons 
 
To investigate participants’ levels of genetic determinism, I asked participants to indicate their 
agreement with a statement from Chapman et al. (2017):  
 
I believe that my destiny is written in my genes 
 
Further, to explore participants’ attitudes towards genomics’ approach to medicine, I asked 
participants to rate their agreement with another statement from Chapman et al. (2017):  
 
Preventing health problems is preferable to curing health problems 
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Finally, I included a set of questions to explore the concept of genetic exceptionalism (Davies, 
2017; see section 1.7.2.4), all measured on a 6-point Likert scale (Strongly agree, Moderately 
agree, Slightly agree, Slightly disagree, Moderately disagree, Strongly disagree). 
 
The next 3 questions consider the various types of medical data that can be stored by the NHS. 
Currently, the NHS keeps medical records which will include keeping track of any appointments 
you may have had with your GP. Please indicate how much you agree with the following 
statements.  
 
• I would feel uncomfortable with the possibility for the NHS to have my genetic data on 
record 
• I feel uncomfortable with the possibility that the NHS have my sexual health data on 
record 
• I feel uncomfortable with the possibility that the NHS have my mental health data on 
record 
 
2.3   Distribution & recruitment 
We recruited participants by emailing a total of 390 community and volunteering groups 
across the UK, as well as science organisations, charities, and personal and academic contacts. 
A breakdown of these is in Appendix 3.4. Of those, 23 replied confirming their distribution of 
the survey, 11 declined, and 356 did not respond (response rate =8.7%). Posters were also 
distributed around libraries in Bristol, including Redland Library, Arts and Social Sciences 
Library, and Queens Library. Posters contained a QR code, so that the lead researcher could 
track the number of participants who completed the survey through this recruitment method. 
However, no participants were recruited via this method.  
 
2.3.1   Obtaining a representative sample: Re-distribution 
We aimed to recruit 300 participants. When I neared the halfway mark (N=145), I analysed 
participant demographics to assess the diversity of my sample. By comparing my data to UK 
census data (Office for National Statistics, 2011), I recognised that my most lacking 
demographics were: Asian participants (UK Census =7.5% vs. My data =2.7%); black 
participants (3.3% vs. 0.7%); participants with no formal qualifications (27% vs. 0%); and 
participants with GCSEs only (29% vs. 2.06%). 
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Therefore, as an attempt to obtain a more representative sample, I took a more targeted 
approach to recruitment. I got in contact with multiple BME (black and minority ethnic) 
student and campaigning groups (see recruitment table in Appendix 3.4). Of those, two 
responded and shared the survey with their group: SU BME Network and Union UCL BME 
Students’ Network. However, no additional participants were obtained.  
 
In addition, I used the survey recruitment site Prolific Academic (Prolific, 2014) and applied 
filters of no formal qualifications or GCSEs only. Through this method, I was able to obtain 
additional participants (n=53) who fulfilled these criteria.  
 
2.4    Data analysis 
Before data analysis commenced, data from Prolific Academic was combined with the original 
data to form one data set (N=430).  An alpha level of .05 was used for all statistical tests.  
 
2.4.1    Data cleaning 
First, data were cleaned to eliminate those who did not finish the survey and/or give final 
consent (n=136, leaving N=294). Second, data from participants who finished the survey in 
under ten minutes (n=15) were eliminated as it was considered unlikely that they would have 
been able to read through all of the necessary information in that time, as the survey was 
estimated to take approximately 15–20 minutes. Finally, participants who were under 18 
(n=3) and not from the UK (n=2) were excluded as they did not fit the research criteria 
(N=270).  
 
2.4.2    Participant demographics 
A total of 270 participants completed the study (170 female, 63%, Mean age =44 years). 
Approximately one-third of participants had at least a bachelor’s degree (or equivalent), 4.8% 
of participants had a doctorate degree (or equivalent), and 17.4% of participants had GCSEs 
only (or equivalent). A large majority of participants were white (92.6%), and the remaining 
participants were Asian, biracial, or other ethnic group - 1.9% (UK Census data =7.5%), 0.7% 
(2.2%), and 4.1% (1%) respectively. There were no black participants (UK Census data =3.3%). 
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There was an almost equal divide between participants who had children (49.3%) and those 
who did not (50%), with the remaining data unavailable, i.e. participants selected ‘Prefer not to 
say’ (0.7%). Most participants had heard of genetic testing (93.3%) but did not work for the 
NHS (93%) or have genetics in their workplace environment (75.2%). Regarding their 
experience with genetic testing, 17.4% of participants indicated they, or someone close to 
them, had had a genetic test carried out by a doctor, but only 2.2% of participants had used an 
online genetic test to assess their genetic health risk. This statistic was slightly higher for use of 











Percentage of participants 
Gender  
Male  35.9 
Female 63 
Data unavailable 1.1 
Age  
18 - 25 23.4 
26 - 35 11.1 
36 - 45 8.5 
46 - 55 23.5 
56 - 65 14.6 
66 - 75 8.5 
76 - 85 4.8 
Data unavailable 5.6 
Highest level of school 
completed 
 
No schooling completed 1.5 
GCSEs  17.4 
A Level or equivalent 9.6 
Trade/technical/vocational 
training or equivalent 
3.7 
Foundation degree or equivalent 1.5 
Bachelor’s degree or equivalent 32.6 
Master’s degree or equivalent 16.7 
Professional training/Grad 
scheme or equivalent 
12.2 
Doctorate or equivalent 4.8 
Ethnicity  
White/White British 92.6 
Asian/Asian British 1.9 




Other ethnic group 4.1 
Data unavailable 0.7 





Data unavailable 0.7 
Works for the NHS?  
Yes 7 
No 93 
Last taught about genetics  
Still studying genetics 9.3 
1 – 5 years ago 11.9 
5 – 10 years ago 10 
10 – 20 years ago 7 
20+ years ago 21.1 
Never taught 40.7 





Not in paid employment 7.8 
Data unavailable .4 
Heard of genetic testing  
Yes 93.3 
No 6.3 
Data unavailable .4 
Had a genetic test by doctor 





Data unavailable .7 
Used online genetic test to 











                           Note. Data unavailable = Participants selected ‘Prefer not to say’.  
 
2.4.3   Scoring of measures 
All scores were calculated using the mean score across items within each measure (biological 
knowledge, clinical knowledge, perception of knowledge, and acceptance of genomic 
medicine). I required participants to have completed 80% of the items in the measure in order 
to generate a score. As a final step, in order to make measures more easily comparable and 
equally weighted in the composites, all were rescaled so that the top score was equal to 1.  
Appendix 3.5 indicates the questions (N=13) that were eliminated from each section following 
reliability tests of Cronbach’s alpha.  
 
2.4.3.1 Biological knowledge of genetics 
Participants’ answers were scored (1 =correct, 0 =incorrect). For the questions 19–22, where 
participants were asked to give heritability estimates for various traits, all responses within 
10% of the correct answer were scored as correct. This measure originally consisted of 25 
items. However, question 5 was excluded because, as it was phrased, I realised there was more 
than one correct answer.  Also, the measure did not reach acceptable reliability (α =.66). Inter-
item correlation analyses revealed that 5 items were not worthy of retention and so were 
eliminated from the final measure (19 items, α =.74) (see Appendix 3.5).  
 
2.4.3.2 Perception of genetic knowledge 
Participants’ answers to these 4 questions were scored to reflect their perceived level of 
knowledge (α =.87). For example, responses of ‘Very good’ to the question ‘When you hear the 
term DNA, how would you rate your understanding of what the term means?’ was given the 
highest score of 4. The final question in this measure was on a 5-point scale and so was 
rescaled so that the top score was equal to 4.  
 






2.4.3.3 Clinical knowledge of genetics in healthcare 
Again, participants’ answers were scored (1 =correct, 0 =incorrect). For question 13, where 
participants were asked to indicate how much they had ‘read or heard about genetic tests that 
predict the likelihood that a person will develop certain genetically influenced diseases or 
conditions’ on a 5-point scale from ‘Not at all’ to ‘Quite a lot’, answers were rescaled to be 
between 0 and 1. The original version of this measure had 17 items, however was deemed not 
reliable (α =.55). Removal of 8 items resulted in an increase in alpha (α = .64) (see Appendix 
3.5). 
 
2.4.3.4 Acceptance of genomic medicine 
Participants’ answers on the Likert scale questions were scored so that the top score of 5 was 
given to those who put ‘Strongly agree’ with statements that implied a level of acceptance 
towards genomic medicine. For example, ‘The benefits that the use of genetics in healthcare will 
bring to our healthcare system far outweigh any potential downsides’. This scoring was reversed 
if participants put ‘Strongly agree’ to statements that indicated a lack of acceptance, for 
example, ‘The use of genetic data to inform medical decisions is overly intrusive’. For question 1, 
which was on a 3-point scale, scores were rescaled so that the top score of 3 was equal to 5. 
The final two questions in this measure, which had three answer options, were scored as 1 and 
0. A score of 1 was given to the answer that indicated higher acceptance of genomic medicine 
and a score of 0 was given to the remaining answer options (α =.83).  
 
2.4.3.5 Additional measures 
Three of the additional measures required scoring. Participants’ level of comfort with the idea 
of their genetic data being held by the NHS was scored on a 5-point scale, with ‘Strongly 
disagree’ on the statement ‘I would feel uncomfortable with the possibility for the NHS to have 
my genetic data on record’ given the highest score of 5. This was repeated for level of comfort 
with both mental health data and sexual health data. The remaining additional questions were 
used as descriptive data.  
 
2.4.4 Data screening 
No variables had more than 10% missing data, so all were included in analyses.  Scores were 
screened for outliers. Scores lower than .2 for acceptance (n=3) and biological knowledge 
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(n=1) were eliminated from further analyses. No other outliers were found with the remaining 
measures. Data was then tested for violation of assumptions of multiple regression. It passed 
tests of normality, linearity, and homoscedasticity (see Appendix 3.6 for results). To investigate 
multicollinearity between predictor variables, a Pearson correlation analysis was conducted. 
As can be seen in Table 2.1, the correlation between biological knowledge (M = .69, SD = .18) 
and clinical knowledge (M = .63, SD = .18) was .80, and thus violates this assumption. 
Therefore, these two predictor variables were combined to form a new variable – ‘Combined 















2.4.5 Statistical analysis: Multiple regression 
2.4.5.1 The role of perception of knowledge 
A second Pearson correlation analysis with all the final measures (i.e. including ‘Combined 
knowledge’) and all other variables revealed that higher scores on perception of knowledge 
were associated with higher scores on acceptance of genomic medicine (see Table 2.2). 
Acceptance was not correlated with combined knowledge. Perception of knowledge and 

















1.  Biological knowledge  -     
2. Clinical knowledge .80** -   
3. Perception of knowledge .55** .51** -  
4. Acceptance of genomic medicine  .06 .03 .15* - 
M .69 .63 .56 .69 
SD .18 .18 .21 .17 
Min .21 .16 .11 .22 
Max 1 1 1 1 
Table 2.1 Means, Standard Deviations, Minimum and Maximum Values, and Pearson 
Correlation Analyses Among Main Variables 
Note. M = Mean. SD = Standard Deviation. Min = Minimum. Max = Maximum. 
* p < .05. ** p < .01. 
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correlation was not high enough to conclude that these two measures were conflated with one 
another.  
 
The correlation results also provide support for the validity of my measures. As expected, both 
combined knowledge and perception of knowledge were positively correlated with education. 
In addition, both were positively correlated with being in a workplace that comes across 
genetic data and negatively correlated with the length of time since participants were taught 
about genetics. Also, combined knowledge was positively correlated with having heard of 
genetic testing prior to the survey and with previous use of an online genetic health risk test. 
Finally, perception of genetic knowledge was correlated with having had a genetic test carried 
out by a doctor. 
 
The correlation results also give us some insight into my sample. The negative correlation 
between being female and being white indicates there were more women that identified as 
Asian, biracial, or other ethnic group than men. The negative correlation between age and 
working for the NHS shows that those participants who worked for the NHS were of a younger 






Table 2.2 Pearson correlation Among All Variables. 





Variable 1 2 3 4 5 6 7 8 9 10 
 
11 12 13 14 15 
1.  Combined knowledge -                
2. Perception of knowledge .55** -              
3. Acceptance of genomics .01 .15* -             
4. Age -.17** -.16* .03 -            
5. Being female -.07 -.11 .00 .08 -           
6. Being white .00 -.01 .06 -.05 -.12* -          
7. Being a parent -.25** -.21** -.01 .63** .06 -.08 -         
8. Education .41** .28** -.02 .14* .08 .12* .01 -        
9. Works for NHS .07 .10 .06 -.14* .12 .02 -.10 .06 -       
10.Time since taught genetics -.39** -.48** -.05 .67** .00 -.05 .51** -.10 -.21** -      
11. Genetics in workplace .26** .23** .01 -.05 .10 .13* .08 .46** .23** .23** -     
12. Heard of genetic testing  .17** .12 .01 .02 .02 .05 .04 .04 .02 .05 .06 -    
13.  Genetic test by doctor .10 .20** .07 -.08 .06 -.01 -.03 -.03 .14* .20* .08 .11 -   
14. Online genetic health risk test  .13* .04 .08 -.07 -.06 .07 .12 .12 .06 .03 .03 .03 .07 -  
15. Online genetic ancestry test .06 .07 .07 -.03 -.05 -.01 .06 .06 .04 .03 -.05 .07 .11 .43** - 
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To explore further, a multiple regression was conducted to investigate the role of perception of 
knowledge (see Table 2.3). Model 1 indicates that perception of knowledge explained 2.4% of 
the variance in acceptance, R2 = .024. Perception of knowledge significantly predicted 
acceptance of genomic medicine (β =.16, p =.014).  
 
In model 2, I adjusted for age and sex as control variables. Perception of knowledge remained a 
significant predictor variable (β =.16, p =.011).  Neither sex nor age significantly predicted 
acceptance. Model 3 allowed us to control for all other covariates such as education, whether 
participants had heard of genetic testing prior to the survey and the time since participants 
were last taught genetics. Again, perception of knowledge remained a significant predictor (β 
=.17, p =.031).  Finally, in model 4 I added combined knowledge as a control variable. 
Perception of knowledge still significantly predicted acceptance of genomic medicine (β =.21, p 
=.017).  Combined knowledge did not predict acceptance (β =.023 p =.720) in either the 
unadjusted or adjusted models. A post-hoc power calculation revealed that I had 90% power to 
detect an effect size of 0.05 and 81% power to detect an effect size of 0.04 at a 95% confidence 

























2.4.6      Additional analyses 
In addition to my main research question, I asked participants some additional questions to 
explore other interesting issues raised by genomic medicine (see section 2.2.1.7).  
 
2.4.6.1  Consent procedure with genetically related family members  
Figure 7.1 indicates the spread of responses given to the statement ‘Family members share 
many genetic traits and may have the same genetic abnormalities associated with disease. 



















Model 1     Model 1     
Perception of knowledge 0.16 
(0.03, 
0.23) 
0.05 .024 .014* Combined knowledge 0.02 
(-0.10, 
0.15) 
0.07 .001 .720 
Model 2 (adjusted for 
age & sex) 
    Model 2 (adjusted for 
age & sex)  
    
Perception of knowledge 0.16 
(0.03, 
0.24) 
0.05 .027 .011* Combined knowledge 0.03 
(-0.10, 
0.16) 
 0.07 .002 .673 
Model 3 (adjusted for all 
demographics***) 
    Model 3 (adjusted for all 
demographics***) 
    
Perception of knowledge 0.17  
(0.01, 
0.27) 
0.07 .060 .031* Combined knowledge -0.01  
(-0.16, 
0.15) 
0.08 .041 .918 
Model 4 (adjusted for all 
demographics*** & 
combined knowledge) 




    
Perception of knowledge 0.21 
(0.03, 
0.31) 
0.07 .065 .017* Combined knowledge -0.09  
(-0.26, 
0.08) 
0.09 .065 .293 
Table 2.3 Enter Multiple Regression Results (Unstandardised B Weights, Standard Error, R2 values, and 
P Values) for Acceptance of Genomic Medicine 
 
  Note. * p < .05. ** p < .01.  
  ***Adjusted for: Age; Sex; Ethnicity; Parental status; Education; Works for the NHS; Time since last 
taught genetics; Genetics in workplace; Heard of genetic testing prior to survey;  Genetic test carried 
out by a doctor; Used online genetic health risk test; Used online genetic ancestry test. 
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gets a genetic test for medical reasons’. There is a clear pattern of responses, with most 
participants strongly (45.2%) or moderately (23.7%) disagreeing. Only 2.2% of participants 
strongly agreed. Overall, the majority of participants (83.3%) somewhat disagreed, with the 
















2.4.6.2     Is my destiny in my genes? 
Figure 7.2 shows the spread of responses to the statement ‘I believe that my destiny is written in 
my genes’. The most popular response was ‘Slightly agree’ (28.3%), followed by ‘Moderately 
disagree’ (21.9%) and ‘Strongly disagree’ (19%). There was an almost even split between 
















































Figure 7.1 Bar chart indicating the spread of answers in response to the statement 
‘Family members share many genetic traits and may have the same genetic 
abnormalities associated with disease. Therefore, all immediate family members 




















2.4.6.3      Is prevention better than cure? 
Figure 7.3 shows participants’ responses to the statement ‘Preventing health problems is 
preferable to curing health problems’. The majority of participants (73.4%) strongly agreed 
with this statement, 18.9% moderately agreed and 5.9% slightly agreed. Overall, a large 
majority (98.2%) of participants somewhat agreed with this statement, with the remaining 

















































Figure 7.2 Bar chart indicating the spread of answers in response to the statement ‘I 


















2.4.6.4      Genetic exceptionalism: Do people have less trust in the NHS 
storing their genetic data than their mental or sexual health data?  
Pearson correlation analyses revealed correlations between feelings of comfort with the three 
different types of data (genetic, mental health, and sexual health) being held by the NHS (Table 
2.6). The highest correlation was between mental health data and genetic data, followed by 
mental health data and sexual health data, and then genetic data and sexual health data. 















































1.1% 0% 0.7% 
Figure 7.3 Bar chart indicating the spread of answers in response to the 







                                
                          
 
 













Figure 7.4 shows the spread of responses for each type of data. For each data type, there was a 
similar distribution of responses. For example, 3.7% of participants responded with ‘Strongly 
agree’ for genetic and sexual health data, with a similar 2.2% for mental health data. Overall, 
79.2% of participants somewhat disagreed (i.e. a combination of all disagree responses) with 
the statement ‘I would feel uncomfortable with the possibility for the NHS to have my genetic 
data on record’, indicating that these participants felt comfortable with the idea of the NHS 
having their genetic data. For mental health data, the proportion of participants that felt this 














    
1. Comfort with genetic data in NHS -    
2. Comfort with sexual health data in NHS .61** -  
3. Comfort with mental health data in NHS .74** .67** - 
M .72 .71 .73 
SD .28 .28 .28 
Min 0 0 0 
Max 1 1 1 
Table 3 Means, Standard Deviations, Minimum and Maximum values, 
and Pearson Correlations Among Comfort with Different Types of Data 
Being Held by the NHS 
 
Note. M = Mean. SD = Standard Deviation. Min = Minimum. Max = 




 Figure 7.4. Bar chart indicating participants’ responses as to how comfortable they would feel 
with  different types of data (sexual health, genetic, & mental health) being held by the NHS.  
 
2.4.6.5 Specific questions with lowest and highest scores 
In order to explore the specifics of participants’ knowledge, the knowledge questions (in the 
combined knowledge measure) with the lowest scores (more than 60% of participants with 
incorrect answer) and the highest scores (more than 85% of participants with correct answer) 
were calculated. For the acceptance measure, the two questions that instigated the least and 
most accepting responses were calculated. 
 
2.4.6.5.1  Knowledge questions with lowest scores 
Table 4.1 below indicates the questions that participants had the most difficulty with. In 
particular, participants struggled to define the term ‘heritability’. In line with this, the majority 
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of participants did not get within 10% of the correct answer when estimating the heritability of 
both weight and school achievement. Finally, 60.7% participants did not know that there are 
approximately 20,000 genes in the human genome.  
 
Table 4.1 Table of the Questions with Highest Amount of Incorrect Responses, and the Percentage 







The word ‘heritability’ means… 
• The proportion of the variation in the physical composition of a 
population accounted for by genetic variation 
• The proportion of a physical composition that is passed on to the next 
generation 
•  The proportion of a person’s characteristic that is accounted for by 
genes 




Approximately how many genes does the human DNA code contain? 
• 2,000  
• 1 million  




On a scale of 0-100 how important do you think genetic differences are 
between people in explaining individual differences in the following traits (with 





On a scale of 0-100 how important do you think genetic differences are 
between people in explaining individual differences in the following traits (with 





Note. Green = the correct response. Red = the most common incorrect response. 
 
In addition, only 28.9% of participants had heard of the 100,000 Genomes Project, and even 
fewer (14.4%) had heard of Genomics England. 
 
2.4.6.5.2  Knowledge questions with highest scores 
Table 4.2 shows the questions that most participants answered correctly. For example. nearly 
all participants understood the mechanism of a one in four chance of a child having a genetic 
disease, (95.9% of participants) and a large majority of participants (93.7%) were aware that 
the study of genetics can lead to better treatments. 
 
Table 4.2 Table of the Questions with Highest Number of Correct Responses, and the Percentage 







A doctor tells a couple that they’ve got a one in four chance of having a child 
with genetic disease, This means... 
• ...if their first three children are healthy, the fourth will have the illness  
• ...if their first child has the illness, the next three will not 
• ...each of the couple's children will have the same risk of suffering from 
the illness 




What is the main function of all genes? 
• Storing information for protein synthesis 
• To provide energy to the cell  
• To clear out waste from the cell  










Which of the following is FALSE: 
• By eating a genetically modified fruit, a person’s genes could also 
become modified 
• The cloning of living things produces genetically identical copies 
• All plants and animals have DNA 
 
87.1% 
There are many common diseases where the study of genetics can show the 
road to better treatment 




The use of patients’ genetic data to deliver targeted therapies is already 
changing people’s lives 




The rapidly expanding role of genetics in many healthcare decisions is already 
increasing the demand for qualified genetics professionals 




Currently, the NHS has every individual patient’s genetic code stored on their 
database 




Note. Green = correct response.  
 
2.4.6.5.3 Acceptance statements with lowest and highest score 
The highest possible score on each acceptance statement was 1, and the lowest 0, with 4 
intermediate scores in between. Thus, if every participant (N=270) responded with the most 
accepting answer on a statement (i.e. giving them a score of 1), the overall score for that 
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statement would equal 270. From this, I could calculate which statements instigated the most 
and least accepting responses in terms of participant attitude to genomic medicine. The 
statement that received the least amount of acceptance was ‘I am concerned about who will 
have access to my genetic data once it is stored within an NHS database’ - agreeing with this 
statement indicated a lack of acceptance. This statement scored 124/270, and Figure 7.5 
demonstrates the spread of responses. Importantly, the arrows on the figure show that this 




















Contrastingly, the statement with the highest score of acceptance was ‘If I was told that 
knowledge of my genetic data may improve the effectiveness of a medical intervention that I 
required, I would not hesitate to have my genetic data tested’. This statement scored 240/270 - 
agreeing with this statement indicated acceptance - and the spread of responses can be seen in 
Figure 7.6. Crucially, the arrows show the large difference between the amount of accepting 
responses versus non-accepting responses. 
 




Figure 7.5 Pie chart indicating the spread of responses to the 
statement ‘I am concerned about who will have access to my genetic 















In this chapter I explored the predictive power of different types of genetic knowledge, i.e. 
biological, clinical, and perception of knowledge, on the acceptance of genomic medicine. My 
study found that UK participants’ knowledge of genetics (a combination of biological and 
clinical knowledge, i.e. combined knowledge) did not predict their acceptance of genomic 
medicine. However, participants’ perception of their genetic knowledge predicted their 
acceptance but with a small effect size, explaining only 2.4% of the variance. Thus, the findings 
in this study do not support the hypothesis that fear of genomic medicine is due to a lack of 
understanding of genetics. Nonetheless, the findings provide some evidence that members of 
the public who perceive themselves to be more knowledgeable about genetics are more 




It is also important to note that, on average, participants scored 66% in the combined 
knowledge measure. This is almost identical to the average score of 65.5% in Chapman et al’s 
(2019) recent study, which the authors described as ‘poor’ given the multiple-choice format of 
questions which greatly increases peoples’ chances of getting the correct answer. Given that 
my questions were also in multiple-choice format, and that a large majority of my sample were 
highly educated - 66.3% were educated to bachelor’s degree level and above - I can come to a 
similar conclusion and suggest that genetic knowledge amongst my sample was poor. This is 
concerning because the mainstreaming of genomic medicine means genetics will become more 
relevant for people in the UK over the coming years; having an understanding of basic genetic 
concepts is likely to help individuals navigate their way through this complex area of medicine.  
 
Whilst this study cannot ascertain cause and effect, I controlled for multiple variables such as 
age, sex, parental status, and experience with genetic testing. The role of perception of 
knowledge remained statistically significant. Further, whilst participants’ combined knowledge 
was positively correlated with their perception of their genetic knowledge, the predictive 
power and significance of perceived knowledge also remained when combined knowledge was 
a control variable. Therefore, independent of how knowledgeable the participants were, their 
perception of their knowledge was more predictive than their actual knowledge. The following 
section will explore these main findings in more detail.  
 
 
2.5.1         Present study: perception of knowledge predicts 
acceptance of genomic medicine 
Previous studies have found factors such as experience with genetic disease (Henneman, 
Timmermans, & Wal, 2006) or trust in science and technology (Gottweis, 2002) are more 
important than genetic knowledge as a predictor of acceptance. Contrastingly, the present 
study indicates that participants’ perception of their genetic knowledge was the most 
important predictor. In my study, participants who were more confident in their genetic 
knowledge were more accepting of genomic medicine. This result makes intuitive sense: 
feeling more confident in your genetic knowledge may also help you feel more prepared for 
any issues that may arise. This would be particularly comforting given that there are so many 
unknowns in genomics. This is in line with previous research that shows having more 
confidence in your own abilities is a powerful tool for long-term health behaviour change 
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(Strecher et al. 1986), which could include changing behaviour in response to genetic results. 
This is particularly important for a smooth transition to difficult changes to health practice - 
genomic medicine represents such a difficult change for many members of the public.  
 
To interpret this result further, it is important to also consider the relationship between 
perceived and actual genetic knowledge (i.e. combined knowledge). Participants displayed a 
level of accuracy when estimating their level of knowledge, however there was room for 
improvement. This is consistent with previous research that indicates people can be inaccurate 
when estimating their level of knowledge (West & Stanovich, 1997). Lanie et al. (2004) 
attributed these inaccurate estimations to increases in exposure to genetic terms from the 
media. Indeed, there have been calls for scientists to advocate more for correct reporting of 
results and the encouragement of realistic understandings of science (Evans et al. 2011). For 
example, it has been suggested to replace the use of the phrase ‘gene versus environment’ with 
‘gene-environment interaction’ (Condit, 2007).  Encouragement of the media to use 
terminology that will foster correct understandings of genetics is particularly vital because the 
public get most of their information about genomics from the media (Parry, 2019).  
 
2.5.2 Present study: no evidence for an association between 
genetic knowledge & acceptance of genomic medicine 
Our finding of a null relationship between genetic knowledge and acceptance of genetics in 
healthcare is in line with findings from previous research (Henneman, Timmermans, & Wal, 
2006; Sturgis, Brunton-Smith, & Fife-Schaw, 2010). This suggests that efforts to educate the 
public with scientific facts about genetics may not have the deficit model’s predicted effect of 
increasing public acceptance of genomic medicine.   
 
In turn, my findings go against the notion of a deficit model (Sturgis & Allen, 2004) and findings 
of a positive relationship (Allum et al. 2014; Chapman et al. 2019; Human Genetics 
Commission, 2001; McClintock, 2019; Pardo et al. 2002) as well as findings of a negative 
relationship (Jallinjoa & Aro, 2000). It may be that the deficit model is incorrect, and that 
people’s knowledge of genetics is not associated with their acceptance of genomic medicine. 
Or, given how quickly the field of genetics in healthcare is changing and that many more people 
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may have had experience with genetic testing, the deficit model may be out-of-date. However, 
it is important to consider alternative reasons for my finding, as discussed below.  
 
2.5.2.1 Use of formal scientific knowledge  
Despite a belief amongst some scientists and policy-makers that ‘to know it [science] is to like 
it’ (Bauer, Petkova, & Boyadjieva, 2000, pg. 42), the present study failed to reveal such a 
finding. However, it is important to point out that ‘loving’ science and being sceptical about 
science and scientific research are not mutually exclusive.  Indeed, one can enjoy and 
appreciate the scientific process but have an awareness of its disadvantages and failings.  
Regardless, my measure of genetic knowledge, both biological and clinical, was based on the 
testing of factual scientific knowledge. Other studies that found a positive association also 
tested factual scientific knowledge (Allum et al. 2014; Human Genetics Consortium, 2001; 
McClintock, 2019). This automatic framing of scientific knowledge in such a general, formal 
way may be overlooking other aspects of scientific knowledge that are equivalently, or indeed 
more, important. Actually, lay understandings of science can be detailed and sophisticated 
without possessing formal scientific knowledge (Sturgis, Cooper, & Fife-Schaw, 2005). For 
example, institutional knowledge, i.e. knowledge of the regulatory framework of science, which 
includes knowledge of the rules and methods involved in data storage and de-identification, as 
well as how data is shared within and across institutions, has been suggested as most 
important in establishing trust in science (Bauer, Petkova, & Boyadjieva, 2000). Given the 
importance of trust in public acceptance of scientific technology (Davies, 2017; Gottweis, 2002; 
Open Data Institute, 2018; Siegrist, 2000), it could be reasonably concluded that institutional 
knowledge is most important in improving public acceptance of genomics. Thus, overall, my 
conceptualisation of ‘knowledge’ as the understanding of the biological mechanisms of genetics 
and the current state of genetics in healthcare may have overlooked other aspects of the 
public’s complex and nuanced understandings of genetics. Bucchi & Neresini (2008, pg. 60) 
summarised this point, ‘Lay knowledge is not an impoverished or quantitatively inferior version 
of expert knowledge; it is qualitatively different.’ Future research could include measures of 






2.5.2.2 Controversial nature of genomics in UK 
Alternatively, my results may be due to Bak’s (2001) finding that the relationship between 
knowledge and acceptance is weaker with more controversial scientific technologies. The UK is 
the world leader in genomic medicine - we have progressed more than any other country in 
making the promise of personalised medicine a reality. Thus, it may be that the UK public 
perceive genomics to represent a threat in a way that other countries do not. In turn, the 
relationship between knowledge of genetics and acceptance of genomic medicine may be 
weakened so much that it ceases to exist.  
 
2.5.2.3 Differences in measures across studies 
Finally, the difference between my findings and the findings of studies that show a significant 
relationship between knowledge and acceptance may be a result of the different measures 
used. In my study, I used a combination of survey questions from multiple sources as well as 
newly constructed questions based on research into common misunderstandings of genetics 
(see 2.2.1 for details of survey development). The development of the measure of knowledge 
was based on both biological and clinical knowledge of genetics. To the best of my knowledge, 
no other study has looked at clinical knowledge of genetics in UK healthcare. The measure was 
validated through its positive associations with education, being in a workplace that comes 
across genetic data, and familiarity and experience with genetic testing, as well as its negative 
correlation with the length of time since participants were taught about genetics. 
 
Studies with results that differed to mine used different measures of knowledge. For example, 
the Human Genetics Commission’s (2001) assessment of participants’ knowledge was less 
extensive; participants were judged only via their ability to appropriately classify 4 
characteristics as completely inherited, e.g. cystic fibrosis. Also, McClintock’s (2019) study was 
an experiment that measured the short-term effect of an intervention using PUGGS (Carver et 
al. 2017).  In contrast, my study was non-experimental and whilst I incorporated some of the 
same questions from the PUGGS, my final measure was substantially different. 
 
Overall, due to the diverse measures used, the different studies may have captured similar yet 
subtly different aspects of genetic knowledge. In turn, the relationship between knowledge and 
acceptance may have been affected. However, whilst plausible, this reasoning implies that the 
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investigated relationship may not have sufficient strength to withstand variation in how it is 
measured.     
 
2.5.3 Additional findings 
In addition to my main research questions, I explored important questions that are raised by 
the continued advancement of genomic medicine in the UK. Below is an exploration of my 
findings. 
 
2.5.3.1 Genetic exceptionalism: Do people have less trust in the NHS 
storing their genetic data than their mental or sexual health data? 
A large majority of participants (79.2%) indicated they felt comfortable with the NHS having 
their genetic data on record. This statistic was slightly higher than the proportion of 
participants who felt this way about mental health data (77.4%) and sexual health data 
(75.6%). Further, feelings of comfort with genetic data correlated highly with feelings of 
comfort with both sexual health data and mental health data. This particular finding, i.e. in the 
context of the NHS having a record of their genetic data, does not provide support for the 
concept ‘genetic exceptionalism’, i.e. the perception that genetic data is different to other types 
of medical data (Davies, 2017). Given that the UK is leading the way with genomic medicine, 
perhaps UK residents are becoming more familiar with genomics and consequently becoming 
more receptive to the idea of genomic medicine. 
 
However, this finding may simply be reflecting the high levels of trust and confidence people 
have in the NHS and doctors (Ipsos MORI, 2013). Such automatic and large feelings of trust in 
an organisation like the NHS may influence individual judgement on certain issues, which 
could include storage of their genetic data. Indeed, future research should explore the public’s 
perception of genetic data being shared with research institutions, commercial companies, or 
with healthcare organisations outside of the UK. Such future work could also explore whether 
the large-scale public trust in the NHS can have a negative impact on individual choice and 
judgement. For example, participants could be presented with a scenario in which there is a 
clear answer as to the most appropriate course of action. However, one group could be given 
this scenario in an NHS context and the other group in the context of a commercial company. 
Differences in responses could reveal whether trust in the NHS can cloud judgement.  
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2.5.3.2 General opinion: genetic relatedness between family members 
& the implications for consent  
A large majority of participants (83.3%) disagreed with the statement ‘all immediate family 
members must give consent before an individual in that family gets a genetic test for medical 
reasons’. This question is linked to one of the main difficulties within genomics – genetic 
relatedness between family members. Perhaps participants believed this would be impractical 
and too difficult to achieve. Alternatively, participants may have felt that personal choice and 
autonomy when making medical decisions is more important than obtaining permission from 
those it may affect. It could also indicate the importance that people attach to maintaining 
patient confidentiality – asking all family members for consent may reveal private information 
about an individual’s medical status. Future research could use qualitative methods to explore 
this finding in more depth in order to provide useful recommendations for practice and 
patient-doctor relationships. 
 
2.5.3.3 General opinion: genetic determinism 
Interestingly, 47.6% of the participants indicated they believed their ‘destiny is written in my 
[their] genes’. Therefore, nearly half of the participants displayed beliefs consistent with 
genetic determinism. This is concerning, particularly given that one-third of our sample has at 
least a bachelor’s degree. This is concerning because it could affect how these individuals may 
interpret genetic results they are given. Given the reputation of the media in constructing 
beliefs of genetic determinism (section 1.6.2.4.1), this finding suggests we should increase our 
efforts to ensure that the media are correctly reporting genetic results and using language that 
does not foster the out-of-date idea that behavior is always caused by either nature or nurture. 
 
2.5.3.4  General opinion: prevention versus cure 
Nearly all participants (98.2%) indicated they believed that preventing health problems is 
preferable to curing health problems. Genomic medicine’s key aim is to understand more about 
disease before it develops (Caulfield, 2019). Researchers are striving for the identification of 
individuals at risk of disease, so that they can administer necessary treatment or precautionary 
measures before the development of disease. Thus, in the eyes of genomic medicine, 
prevention is preferable to cure. So, this finding indicates nearly all participants support the 
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main ethos of genomic medicine, possibly without being consciously aware of it. Future 
research could explore whether increased communication of this message improves 
acceptance of genomics.  
 
2.5.3.5 The specifics of knowledge  
A large majority of participants demonstrated that they understood the basics of genetics, such 
as the fact that a single gene can influence several different traits or diseases. Where 
participants struggled, however, was with the definition and application of heritability 
estimates and, similar to Chapman et al’s (2017) study that found less than 50% of participants 
were aware of the number of genes in DNA, 60.7% of the participants in my study also failed to 
answer this correctly. Knowledge of the public’s weaker areas of genetic knowledge can help to 
guide education efforts.  
 
2.5.3.6 The specifics of acceptance 
Finally, my additional analyses revealed that the statement with the lowest score of acceptance 
was ‘I am concerned about who will have access to my genetic data once it is stored within an 
NHS database’. This contradicts my aforementioned result that 80% of participants were 
happy with their data being stored on an NHS database, and confirms the need for further 
research. Contrastingly, the statement with the highest score of acceptance was ‘If I was told 
that knowledge of my genetic data may improve the effectiveness of a medical intervention 
that I required, I would not hesitate to have my genetic data tested’. Overall, these results 
indicate that participants were most concerned about third party access to their data but 
would also have a genetic test if it meant improving a required treatment. Future research 
could explore whether participants feel their concerns outweigh their perceived benefits and 
future NHS consent materials should be very clear about whether or not the data will be used 
by third parties. 
 
2.5.4 Limitations 
Our study provides important and novel evidence that higher confidence in genetic knowledge 
is associated with increased acceptance of genomics, but it is not without limitations. First, I 
did not manage to recruit enough Asian, biracial, or black participants. This is important as 
people of colour are more concerned about the rise of genomics leading to racial 
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discrimination (Goldenberg et al. 2011; Zimmerman et al. 2006). Therefore, I am likely to have 
missed an important perspective that may have influenced results. Further, participants who 
were Asian or biracial were also more likely to identify as female. This means the data was 
lacking in Asian and biracial men, and that my sample is likely to have overrepresented the 
white male perspective. Further, those in my sample who worked for the NHS were also more 
likely to be younger. Again, this is important because I may have missed influential opinions of 
those who have more experience working in the NHS. However, this was not a survey aimed at 
individuals working in the NHS and the opinion of healthcare professionals specifically was 
beyond the scope of this project. 
 
Second, my survey was framed so that participants were asked biological and clinical questions 
first and their perceptions of knowledge second. This may have resulted in ratings of 
perception that were not truly representative of participants’ confidence in their knowledge in 
their everyday life as it may have knocked the confidence of some but boosted the confidence 
of others, particularly as the survey was designed to be difficult. However, I did not give 
participants feedback. So, arguably, this may have actually provided more accurate ratings of 
confidence as they would have been a reflection of participants’ actual knowledge as well as 
their confidence. Those who felt they got more correct, i.e. due to both higher confidence in 
their knowledge as well as better actual knowledge, were likely to consequently give higher 
ratings of confidence. Further, my measure of confidence in knowledge may actually reflect 
participants’ conscientiousness or perfectionism.  
 
Third, it is important to consider that my measure of perception of genetic knowledge may 
reflect something other than what it intended to measure. For example, estimates may actually 
indicate participants’ broader level of confidence and/or self-esteem; more confident 
participants with higher self-esteem, regardless of their level of confidence specific to their 
genetic knowledge, may have given themselves higher scores on the perception of knowledge 
measure than their less confident counterparts. Indeed, other studies that explore genetic 
knowledge include measures of personality as it is established that this can affect your 
attitudes towards genomic medicine (Chapman et al. 2019). Therefore, future research should 
include a personality measure in order to control for the effects of general confidence on 
confidence in genetic knowledge. We could then establish whether acceptance is linked to 
subject-specific confidence or confidence more generally.  
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Finally, previous research indicates the importance of social class in shaping people’s opinion 
on genomics (Sturgis, Cooper, & Fife-Schaw, 2005). However, I did not include a measure of 
social class, and thus were not able to explore its role in shaping either people’s opinion or 
their knowledge. However, I did attempt to obtain a representative spread of educational levels 
and this in part makes up the social class scale.  
 
2.6  Chapter summary 
In this chapter, I designed, distributed, and collected data using a survey that explored 
participants’ biological knowledge of genetics, clinical knowledge of genetics in healthcare, 
perception of their genetic knowledge, and their acceptance of genomic medicine. My results 
indicated that neither biological nor clinical knowledge predicted participants’ acceptance of 
genomics. Participants’ perception of their genetic knowledge was found to predict acceptance, 
but with a small effect size. Whilst it may be that the deficit model is incorrect or out-of-date, I 
also considered alternative reasons for my finding. This chapter also considered some 
























Chapter 3: Qualitative study – An 
exploration of an informed public’s 
opinion of genetics in healthcare 
 
3.1 Introduction 
Genomic medicine is a controversial topic. Public concerns include: the use of genetic data by 
insurance companies (Cook, 1999; Geer et al. 2001; Hall et al. 2005; Lemke et al. 2010; 
Stockdale, Cassell, & Ford, 2018), employers (Geller et al. 2002; Tambor et al. 2002), or 
commercial companies (Hapgood et al. 2004; Middleton et al. 2019; Trinidad et al. 2010), the 
use of genetic data for reasons other than their own medical benefit, e.g. discrimination; the 
potential for damages to medical privacy from sharing their genetic data for research (Anderlik 
& Rothstein, 2001; Gill & Richards, 1998; Kaufman et al. 2009); and feeling that their data is 
not safe and secure within the NHS (Stockdale, Cassell, & Ford, 2018). These concerns are 
discussed in more detail in section 1.7. 
 
Ultimately, these anxieties stem from the unique nature of genetic data which challenges 
conventional practices of consent and confidentiality (see section 1.5.3 for more detail). Firstly, 
regarding confidentiality, genetic test results for one individual have the potential to affect a 
multitude of others who share DNA. Confidentiality is tested further by the fact that a patient 
must share their phenotypic data (i.e. their medical records) to ensure their genetic data is 
clinically useful. Secondly, the prospect of discovering genetic variants of diagnostic 
significance not linked to the primary reason for the genetic test raises difficulties with consent 
(Mackley & Capps, 2017). Overall, these distinct features of genetic data arguably make it stand 
out from other types of health data. Indeed, this may help to explain the reasons behind 
‘genetic exceptionalism’, whereby people feel genetic data is categorically different to other 
types of data (Davies, 2017). In Chapter 2, my quantitative study did not find any evidence for 
this (see section 2.5.3.1), however may have been confounded by high levels of trust in the NHS 
(REF).  Further qualitative exploration is needed to provide more insight into genetic 
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exceptionalism amongst the UK public and to unpick exactly what it is about genetic data that 
may foster feelings of unease amongst the general public. 
 
These complex concerns have not gone unnoticed by the scientific or medical community; an 
open dialogue has been established to provide a space for the discussion of ethical issues. For 
example, the former ‘European Meeting on Psychosocial Aspects of Genetics’ (EMPAG) has, 
since 2019, been added to the larger ‘European Society of Human Genetics’ conference, 
indicating the recognition that it needed to become part of the broader conversation about 
genomics (European Society of Human Genetics, 2018). Further, in the Chief Medical Officer’s 
2016 annual report entitled ‘Generation Genome’, an entire chapter was dedicated to the ethics 
and the implications for the NHS (Davies, 2017), and the Wellcome Genome Campus has a 
whole department dedicated to society and ethics research (Wellcome Genome Campus, 2019). 
In fact, recognition of these issues dates back to the Human Genome Project, where 3-5% of the 
annual budget was set aside for the exploration of ethical, legal and social issues (Sansgiry & 
Kulkarni, 2003). 
 
However, whilst these initiatives are admirable, more research is required to deepen our 
understanding of the public’s perception both of the ethical issues in genomics and of genomic 
medicine more broadly. This will help to inform our responses to the difficulties that arise from 
the use of genetic data in healthcare. Given the aforementioned complex and controversial 
nature of genomic medicine, qualitative research may offer a more useful contribution to this 
work; it allows a depth of insight and may help to tease out complexities in a way that is not 
possible in quantitative research, as well as possibly providing public led suggestions for future 
healthcare practices. 
 
Thus, the present study sought to deepen our understanding of the UK public’s perception of 
genetics in healthcare (the importance of research into the UK public is discussed in section 
1.9.2). I conducted two focus groups to explore public opinion and thoughts on the use of 
genetic data in healthcare. Unlike previous qualitative research (Bates et al. 2005; Stockdale, 
Cassell & Ford, 2018; Waters, Ball, & Gehlert, 2017), participants in my study were given 
information about the current state of genomic medicine in the UK. This was in order to gather 
opinion about genomic medicine as it exists now, as opposed to opinions based on false 
information and/or ideas. Overall, this was an exploratory study with no specific hypothesis, 
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but an aim to provide findings that may help to guide communication and public engagement 
efforts within genomic medicine. 
 
3.2 Methods 
We used focus groups to obtain a broad range of detailed information which I analysed using 
the General Inductive Approach (Thomas, 2003). 
 
3.2.1 Ethical approval & informed consent 
Ethical approval was granted on 9th April 2019 from the University of Bristol School of 
Psychological Sciences Research Ethics Committee (SREC) (see Appendix 4 for details).  
 
Participants received Participant Information Sheets (PIS) in advance of the focus group. This 
informed the participants that the conversation would be recorded and transcribed by a 
transcription service, and that the data would be kept anonymous as names would not be 
transcribed. Paper consent forms were given to participants upon arrival, that assured 
participants of the confidential nature of the data. Participants were given as much time as they 
required in which to decide to consent. Before commencing the focus group, the lead 
researcher ensured all participants had read the PIS and the consent form, and that they were 
given an opportunity to ask questions. The lead researcher then gave participants a verbal 
overview of how the session would go forward. Written consent was obtained from all 
participants.  
 
3.2.2 Data protection & confidentiality 
The completed consent forms and participant demographic information sheets were stored in 
separate, safe and secure locations by the lead researcher. Recordings were made on 
university-owned dictaphones. The audio recordings were sent to University Transcriptions 
(www.universitytranscriptions.co.uk) and were all checked against the recordings by the lead 
researcher to check that technical language had been transcribed correctly. After transcription, 
the audio recordings were deleted. All identifiable information (i.e. names) were removed and 
replaced with participant ID numbers. The anonymised transcripts were stored separately 
from the consent forms and participant demographic information sheets so that no link could 





3.2.3 Participant identification & recruitment 
Convenience sampling was used. Participants had to be over 18, a UK resident, and have 
English as their first language or an equivalent level of fluency. Posters displaying the details of 
the study, the reimbursement amount (£10), and the contact information of the lead 
researcher were distributed around Bristol. Distribution locations included: 
 
• Cotham Pharmacy & Post Office, Cotham 
• Redland Library, Redland 
• Arts and Social Sciences Library, University of Bristol 
• The Canteen, Stokes Croft 
• Café Kino, Stokes Croft 
• The Arts House, Stokes Croft 
• Salvation Army, Stokes Croft 
• Tuck News, Cotham 
• The Cotham Arms  
• St Peter’s Hospice, Stokes Croft 
 
Potential participants expressed interest via email. The lead researcher responded by sending 
information about the structure of the focus group and a copy of the PIS. Participants were also 
asked for basic demographic information (age, sex, & ethnicity). Recruitment continued until 
16 participants who met the inclusion criteria (2 x focus groups of 8 participants) were 
confirmed. A week before each focus group, each enrolled participant was sent a reminder. All 
but one of the participants attended the focus groups (N = 15). 
 
3.2.4 Data collection & focus group conduct 
The focus groups were conducted in the School of Psychological Science common room. The 
lead researcher led the focus group, and Dr Robyn Wootton was also present to make notes 
about body language and other details not captured by the recording. Participants were first 
given a brief presentation about the current state of genetics in healthcare, using information 
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from the NHS (2016). This began with the showing of an approximately 6-minute clip ‘Whole 
Genome Sequencing and You’ (Icahn School of Medicine, 2012). This video detailed: the 
biological structure and function of DNA and proteins; the technology of whole genome 
sequencing; that genetic variants and the environment can influence your risk of developing 
common diseases; that variants in your genome can influence your response to medication; 
that specific genetic variants can lead to the development of serious and/or rare disease; and 
the existence of variants of unknown significance. This clip was chosen as, in the judgement of 
the lead researcher, it gave a balanced view of genetics in healthcare and accurate information. 
This clip was followed by a 5-minute presentation from the lead researcher, that detailed: the 
timeline of genomic medicine; what the NHS currently tests for, i.e. monogenic disorders, 
cancer, and high penetrance mutations; and how developments in research may lead to a 
system of ‘personalised medicine’ in the NHS. I did not discuss issues such as data protection 
and privacy in this introduction. Conversation was then prompted by questions from the lead 
researcher, which were both displayed on the presentation slides and read out verbally.  A list 
of these questions can be seen in Appendix 5. The presentation slides can be seen in Appendix 
6.  
 
The questions used were largely adapted from the ‘Acceptance of genetics in healthcare’ 
section of the survey (see section 2.2.1.6). Additional questions such as: ‘Would you have your 
genetic data tested by the NHS if you were trying for a baby and wanted to know your carrier 
status?’ and ‘Would you have your genetic data tested by the NHS if you were at risk of carrying a 
high penetrance mutation?’ and ‘Would you want to know any information about your genetic 
sequence other than the specific genetic variant under investigation?’ were largely included as 
warm-up questions but also helped to explore participant attitudes towards different types of 
genetic tests. Field notes were taken by Dr. Robyn Wootton however were not included in 
analysis as they weren’t considered to add anything beyond the transcript. 
 
Both focus groups were audio-recorded and transcribed by an external service (described in 
3.3.2). The accuracy of the transcripts was checked by replaying the audio recordings whilst 
simultaneously reading the transcripts. Necessary amendments were made. Transcripts were 
not returned to participants for notes. 
 
3.4 Data analysis 
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Data analysis began after receipt of both transcripts. The transcripts were read multiple times 
to ensure data immersion. I used the General Inductive Approach to analyse the data: 
frequently arising topics were identified and transcripts were coded accordingly. These topics 
were then combined to form broader topics (Thomas, 2003). See Appendix 7 for coding tree. 
Topics were coded as they emerged from the data. Both transcripts were coded by the lead 
researcher, and individual quotes were reorganised in a separate documentation to form a list 
of quotes under each topic heading. To improve the rigour of the analysis, final topics were 
discussed and agreed upon with an external researcher. Participants were not given the 
opportunity to respond to the results.  
 
3.5 Reflexivity 
3.5.1 Personal characteristics 
Both focus groups were conducted in person, thus participants knew that both the lead 
researcher and Dr Robyn Wootton were white, able-bodied women in their twenties. 
Participants were also conscious that we were researchers at the University of Bristol. This had 
a noticeable effect on the dynamics of the focus groups, particularly the group with an all-
student sample. Participants asked multiple questions about genes and how they work in the 
body and about the current state and future of genomic medicine.  We chose to answer 
questions to the best of our ability in order to allow participants to give their opinion from an 
informed point of view. However, on reflection, this led to an expert-learner dynamic between 
the researchers and participants. Whilst it was important to us that the participants felt 
informed about genomic medicine, future research could take steps to ensure that such a 
dynamic would not be repeated. For example, the presentation slide with the text ‘Any 
questions?’, could be changed to ‘Any comments?’  
 
Further, the lead researcher is interested in aiding the development of genomic medicine. The 
position taken by the lead researcher is that genomics has enormous potential for medical 
advancement. Indeed, whilst concerns regarding issues such as privacy are not unfounded and, 
of course, there is always the possibility of illegal access to and use of genetic data, in order to 
realise the enormous potential of genomics and to enable the correct interpretation of new 
genomic data, it is of central importance to be able to link patients’ phenotypic data with their 
genomic data. This requires individuals to give consent for their data to be shared. Thus, whilst 
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care was taken to answer participants’ questions in an unbiased way, it is possible that the lead 
researcher’s personal views were apparent. 
 
 
3.5.2 Relationship with participants 
Two of the participants in the first focus group were friends of the lead researcher, and every 
participant in this group was a student of a similar age to the lead researcher (22 years). In 
contrast, there was a broader range in age in the second focus group (26 – 66 years) and none 
of these participants were students or previously known to the researcher. The differences 
between the groups’ ages, student status, and relationship with the lead researcher may have 
influenced the dynamics between the researcher and participants. Also, it was noticeable that 
some participants spoke more than others. Overall, however, a good rapport between 
researchers and participants was created. Every participant spoke at least once.  
 
3.6 Sample description 
Sixteen participants (2 x groups of 8) were enrolled in the study (N =16). However, one 
participant in the first focus group did not attend (N =15). All participants had responded to a 
poster advert. Table 5 details the characteristics of this sample. 
 
 




n = 4 
Female 
n = 3 
Male 
n = 3 
Female 
n = 5 
Age     






26, 60,  
28, 66 
Data not available 0 0 0 1 
Highest level of school completed     
No schooling completed 0 0 0 0 
GCSEs 0 0 0 1 
A Level or equivalent 3 0  0 






Six topics were identified from the transcripts, including: ‘detrimental psychological impact of 
genetic results’, ‘disclosure and discrimination’, ‘family planning’, ‘knowledge is power’, 
‘genetic exceptionalism: “DNA is different”’ and ‘charting possible futures’. Below I summarise 
Trade/technical/vocational training 
or equivalent 
0 0 2 0 
Bachelor’s degree or equivalent 0 1 1 3 
Master’s degree or equivalent 1 2 0 1 
Professional training/Grad scheme or 
equivalent 
0 0 0 0 
Doctorate or equivalent 0 0 0 0 
Ethnicity     
White/White British 3 1 3 4 
Asian/Asian British 1 0 0 1 
Biracial/Biracial British 0 1 0 0 
Black/African/Caribbean/Black 
British 
0 0 0 0 
Other ethnic group 0 1 0 0 
Parent?     
Yes 0 0 0 2 
No 4 3 3 3 
Works for the NHS?     
Yes 0 1 0 0 
No 4 2 3 5 
Last taught about genetics     
Still studying genetics 0 0 1 0 
1 – 5 years ago 3 2 0 0 
5 – 10 years ago 1 1 1 1 
10 – 20 years ago 0 0 1 0 
20+ years ago 0 0 0 0 
Never taught 0 0 0 4 
Genetics in workplace 
environment? 
    
Yes 1 1 1 0 
No 3 2 2 5 
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each theme and provide quotes that are representative of the discussions relating to these 
themes. 
 
3.7.1 Detrimental psychological impact of genetic results 
Participants discussed the potential for their genetic test results to cause them “anxiety and 
frustration” (ID=F2; Female; Focus group 1). This was in reference to both results for a 
monogenic disorder, e.g. Huntington’s, and for illnesses that can be caused by high penetrance 
mutations or multiple genetic variants of small effect. Due to the potential for anxiety-inducing 
results, some participants felt that it would be better for your mental health to not know your 
genetic risk for disease, “ignorance is happiness as well” (ID=F3; Female; Focus group 1). 
 
… some of it [genetic results] might be quite overwhelming I 
guess (…) if you could get cancer or Alzheimer’s or dementia, 
all those types of things. (ID=M1; Male; Focus group 2) 
 
There was a sense that a genetic diagnosis may loom over you, particularly if the test was for a 
late-onset disease such as Alzheimer’s. Participants felt that the diagnosis could impede upon 
your enjoyment of life in the present moment, as it could induce stress and be “forty years of 
like… thinking about, ‘Oh, it’s going to happen.’” (ID=F5; Female; Focus group 2). Indeed, one 
participant described such a diagnosis as “a death sentence” (ID=F3; Female; Focus group 2).  
 
I reckon I would exaggerate, even if they said you’ve got an 
extra 5% to 10% chance of something, I’d be like, “Oh, Jesus” I’d 
be like, “Oh, God, I’m going to get it, aren’t I?”  That what I feel 
like.  So, I think I’d stress myself. (ID=M2; Male; Focus group 1) 
 
The possibility of an unfavourable reaction to genetic results was highlighted at a different 
angle; one woman touched on how the state of your mental health may influence how well you 
may be able to handle the information in the first place, rather than in response to the results. 
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I think it [effect of receiving genetic test results] depends on 
your mental health and if you are capable of knowing the 
information or not. (ID=F3; Female; Focus group 1) 
 
One man felt that there was a lack of evidence regarding the effect that genetic results may 
have on your mental health and thus lessened his motivation to take part as he did not want to 
take the risk. 
 
You don’t really know the psychological side at all really and 
the effects that it is going to have.  So, I would definitely hold 
off, (…) maybe if it was like a hundred years after or fifty 
years after it had already been released and stuff and there 
was data to suggest that it did or didn’t do certain things 
through psychology and stuff, then maybe it would be a 
different case.  But because you’re the kind of first wave, you 
may be even second wave it’s like… you don’t really want to 
take that risk for yourself. (ID=M2; Male; Focus group 1) 
 
A topic that came up frequently was the power of the mind after being told your diagnosis. 
Participants spoke about how anxiety from genetic results could manifest itself as 
hypochondria, whereby they may interpret standard sensations and bodily functions as signs 
of the illness for which they were (hypothetically) at genetic risk. Others discussed how the 
knowledge of your genetic risk may make the illness itself worse, as you may be “waiting for it 
to happen” (ID=F3; Female; Focus group 2) or that it may cause “some kind of internal stress” 
(ID=M3; Male; Focus group 1). 
 
 
Do you reckon it could affect you mentally if you knew you had 
a high chance of something really bad, you could get really 
anxious about it and stuff and turn into a hypochondriac? 




(…) but then it’s an odd thing because my older daughter was a 
nurse and she said… and I’ve had friends that have been told, 
“You’ve got six months to live” and almost to the day they’ve 
died.  And my older daughter was saying, “The problem is, you 
tell somebody that and it’s almost that they start dying almost, 
waiting for it to happen.” (ID=F3; Female; Focus group 2) 
 
Some participants were concerned about the legacy their results would have on family 
members. Indeed, one participant considered the possibility that knowledge of your genetic 
risk may induce anxiety in your children about diseases they may develop.  
 
…if you were passing on your genome… sorry, your data to your 
offspring is it if you have a… a disease that they could 
potentially get, is that going to cause undue stress on them 




…I would want to know for myself but if it could affect other 
people that I loved then maybe I wouldn’t want to know. 
(ID=M3; Male; Focus group 2) 
 
 
I don’t want to mess about, if I’m having a child, I’m not sure if I 
should be knowing these things.  But at the same time, I could 
be condemning that kid to a life of hell, if you know what I 
mean? With their future development… It would be quite 
interesting to know but at the same time, it would be quite… 
“Oh, fuck…”  Sorry… it might be overwhelming for some people 
… (ID=M1; Male; Focus group 2) 
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3.7.2 Disclosure & discrimination 
A common thread throughout participants’ discussions was their concerns regarding the 
sharing of their genetic data with parties outside of the healthcare system. For example, 
participants discussed the possibility for their genetic data to be given to the police, and 
concerns about whether insurance companies may have access to the information was a 
particular worry for several of the participants. Another common thread that arose was the 
possibility of discriminatory behaviour arising from some people having “a really good 
genome” (ID=M2; Male; Focus group 1), with the implication being that another individual 
could have a ‘really bad’ genome. Indeed, one woman was concerned that “decisions might be 
made because of people’s genetics” (ID=F3; Female; Focus group 2). Participants also discussed 
the potential for genetic data to be used in a political regime, with one woman touching on the 
potential for a eugenics-like, “Hitler-y” movement (ID=F4; Female; Focus group 2). Whilst most 
participants perceived the possibility of discriminatory behaviour to be undesirable, one 
participant suggested that it was not that big of a concern, as it would be “just another thing 
that happens in society” (ID=M3; Male; Focus group 2). 
 
 
…[I am] worried about the storage of information and if it’s 
used for insurance and employers or the police, supposing 
somebody makes a mistake or… (…) so hoping that it wouldn’t 
be used intrusively. (ID=F1; Female; Focus group 2) 
 
 
… it [decision to share genetic info] depends where the 
information goes.  If it’s solely kept within the NHS or if it’s 
shared to say, for instance, insurance companies, I think that 
could potentially be quite dangerous. (ID=M3; Male; Focus 
group 2) 
 (…) you never know what could happen, you don’t know what 
kind of regime might come in… that’s just one example, a 
regime could come into politics or something and take 
control… anything could happen.  It’s not safe forever and there 
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are those links [between genetic data and personal identifiers] 
and there is the ability, it does still exist, to be able to identify 
you with genetic makeup, you never know what is being done 
with it.  It’s like Edward Snowden’s case of him leaking the stuff 
that the government was doing, spying on people that wasn’t 
exactly legal.  Stuff can still be happening even though you 
don’t know it’s happening… you just gotta be aware of those 
things. (ID=M1; Male; Focus group 1) 
 
 
One woman was concerned about the implications of an employer having access to her genetic 
data. She felt that this increased the intrusiveness of an already-intrusive experience of a 
health screening. The participant described the possibility that she could be discriminated 
against even if she refused to share her genetic data, as employers could interpret that decision 
as an attempt to hide important information.  
 
 
…I think it [my concerns] would be, yes, where it could go in 
terms of discrimination potentially, if it got to employers or if it 
became something that people would want to see in terms of 
employers’ health screening.  So, I’ve had one health screening 
of “Are you fit to work for this company?” and it’s very intrusive 
anyway, let alone if they then potentially could say, “Would you 
give us access to that [genetic data]?”  And if you say no… 
obviously, maybe they couldn’t but then that would 
discriminate them against you, “Oh, she hasn’t decided to share 
that information” (…) That is the type of thing I’d be worried 
about…like is she hiding something? (ID=F5; Female; Focus 
group 2) 
Participants also discussed how knowledge of their genetic data may influence their status as a 
romantic partner. It was suggested that potential partners may discriminate against you 
because of your genetic make-up. For example, they may decide to not start a family with you 
“if you’ve got certain [genetic] aspects” (ID=F4; Female; Focus group 1). One man also brought 
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up the possibility that knowledge of your genetic data may influence your experience of the 
dating world, as you may be burdened with the decision as to whether or not to share that 
information with potential partners. 
 
 
 People might say, “Oh, what’s your gene sequence like?”  They 
might not want to have kids with you if you’ve got certain 
aspects. (ID=F4; Female; Focus group 1) 
 
 
There might be a separate area [for genetic data] on [the 
dating app] Tinder. (ID=M2; Male; Focus group 1) 
 
 
M3: (…)if you were young and you got tested and you found out 
you had something (…) legally and morally, do you have to tell 
the person that you have this and there is a chance, or do you 
hold it back and it’s going to be on your records somewhere?  
It’s going to be confidential, but those kinds of things come up 




Participants discussed the importance of anonymity and how this would influence their 
decision to have a genetic test, “…if it was like all anonymous and something, maybe I’d be much 
more likely to get it” (ID=M3; Male; Focus group 1). Some participants felt they were more 
likely to get a test if the results were anonymous. Participants also questioned the extent to 
which genetic data could be completely anonymised and highlighted the uncertainty of future 
legislation regarding the anonymisation of data. 
 Would you ever be able to dispose of the data if you had it 
done and then there was going to be some change in laws or 
legislature, something like that; would you be able to say you 
don’t want it on the system anymore?  You said it’s anonymous, 
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But since it [genetic data] is anonymised why do we even care.  
No one is going to blame you for anything so it would be fine. 
(ID=F1; Female; Focus group 1) 
 
 
…that [decision to share anonymised genetic data for medical 
research] depends on the future, what we were saying is, at the 
moment, in the UK, certain things are protected but it’s just in 
the future what can happen, rules can change.  And so, by doing 
that, it then perhaps won’t be anonymous at some point in the 
future.  I don’t know if that would make a difference, but I think 
it would.  Somebody saying to you that if you can tell us this 
and it’s anonymous and you say yes, but in fact, twenty-five 
years down the line, they decide to not be anonymous and you 
still have family members, children, grandchildren around.  I 
don’t know how I’d feel about that really because things have 
happened in the past, do you know what I mean?  When things 
change in the future it gets very different. (ID=F3; Female; 
Focus group 2) 
 
 
How anonymous can you really make it if it’s all of your 
personal data? (ID=F4; Female; Focus group 1) 
 
 
… in the future I do have concerns about where that [my 
genetic data] goes and how far it goes and what it turns into.  
Just like everything we were talking about like data protection 
and things like that… (ID=F4; Female; Focus group 2 
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3.7.3 Family planning 
Participants discussed the potential for genetic results to have an impact on their plans to have 
children in the first instance. This was in terms of their risk of genetic disease, “I’m more 
concerned about if I would pass something onto my child” (ID=M1; Male; Focus group 2). 
Participants noted that, whilst knowledge of their genetic data could enable a more informed 
decision as to whether or not to start a family, remaining unaware would mean they wouldn’t 
have the burden of making such an informed decision. Further, one man discussed how the 
potential for knowing your carrier status may result in unwanted pressure from your friends 
and family to not start a family.  
 
 
I think I’d want to know [carrier status], probably a bit 
controversial sounding, I’d want to know because if in not 
doing so, then you’re causing a lot of pain to somebody, then 




 I guess I would like to because I don’t have children, to say 
I do want to have children, it would be cool to know if I have 
that [monogenic disorder] and I’ve passed that on, do you know 
what I mean?  But at the same time, I don’t want to… I don’t 
want to know because that might affect my stance of having 




Is it possible that you might be talking to people, your family or 
friends that you were going to have your carrier status tested 
and then, there could be a level of peer pressure put on you by 
other people… basically, they would probably ask, “What are 
you going to do if you find out this or that?”  And then you 
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might almost feel pressured into not having a baby if… and you 
might want to… there could be that? (ID=M2; Male; Focus 
group 1) 
 
3.7.4 Knowledge is power 
Knowledge of your genetic data was also considered to have the ability to empower you to live 
your life to the full, as you would “..know where you are” (ID=F3; Female; Focus group 2). For 
example, participants noted that this knowledge could enable them to appreciate the people in 
their life more, and to make more informed decisions regarding employment.  
 
 
But then, say if you were to develop Huntington’s or something 
which might kick in when you might actually only be active 
when you’re like thirty or something, I don’t really know the full 
details.  Surely that would be a good thing to know because you 
could… this is just a random example, but you could spend your 
life like doing a job which you’re not really enjoying that much 
but saving up for the future.  And then you end up that you 
develop Huntington’s after that whereas, if you knew, you 




… my mum had Motor Neurone and so she had two years, and 
two years is what she had.  And my dad said to me that he got 
so much closer to her, that he cuddled her more and cherished 
her because he did everything for her (…) so, I just think it 
[knowledge of genetic risk] might well give you the time to (…) 
perhaps just to make people aware that you love them because 
we don’t go around telling people we love them.  So, in one way 
I see that knowledge is power to change that ignorance. 




Knowledge of your genetic data was also suggested to give medical professionals more power 
to tailor treatments to improve outcomes. Participants also noted that the development of such 
tailored treatments could save money and increase the efficiency of the NHS.  One man also 
described the idea that we could use our knowledge of the function of genes to identify and 
eliminate the genetic cause of a disease in an individual patient.  
 
 
Yes, I think a tailored treatment would be really fantastic, that 
is what I’m most optimistic about is, yes… tailored treatment, if 
they knew they wouldn’t have to go through possibly as many 
different things, like, “Oh, let’s give them this.  Oh, they’re not 
responding… oh, let’s try something else.”  And I think if they 
could think, “Oh, this person is more likely to respond to this” 
from the start, I think that would be really great. (ID=F5; 




…so, if they can tweak medicines or whatever to treat certain 
conditions that are passed on, you know, some awful conditions 
that children especially have to live with.  If they can somehow 
help those hopefully, I would feel very optimistic about genetics 




…[genomic medicine] would make treatment a lot cheaper and 
a lot more straightforward than having to guess and come up 
with different routes I guess, yes. (ID=F3, Female, Focus group 
1) 





It will save money in the long run as well because you won’t be 
wasting different treatments first, you would just know how to 
treat them. (ID=F2; Female; Focus group 1) 
 
 
They could suppress a gene with medicine or something, if they 
knew you had it, then go, “Take this tablet.” And you’re fine, you 




Participants described how being informed about their genetic risk for disease could enable 
more effective preparation for illness. With regards to breast cancer, preventative measures 
such as a more frequent uptake of mammograms or a double mastectomy were discussed in 
both focus groups. Preparation was also discussed in relation to other family members, “I 
would want to be mentally prepared so that I wouldn’t be a burden on them [my children]” 
(ID=F5; Female; Focus group 2), avoiding illness altogether, “I’d rather take myself to 
Switzerland a bit earlier and do the deed than get Alzheimer’s” (ID=F3; Female; Focus group 1), 
as well as the practicalities of preparing for death, “she arranged what she wanted for her 
funeral, she arranged all her financial stuff” (ID=F3; Female; Focus group 2). 
 
 
But like breast cancer, you could have a mammogram more 
frequently than people normally usually have mammograms.  
So, you could prevent or catch it earlier so, if you had the… 
what sequence… the BR…? (ID=F3; Female; Focus group 1) 
BRCA. (ID=M2; Male; Focus group 1) 





With breast cancer, I’ve heard that… I don’t know if I’m right, 
I’ve heard something along the lines of if a woman does know 
and they have a double mastectomy that can increase their 
chances if they know in advance.  I’ve heard something like 
that, but I don’t know if it was… (…) So, I think that is like a 
preventative thing would be, for me, I would want to know. 
(ID=F2; Female; Focus group 2) 
 
 
…[I would get genetically tested] with a view with not trying to 
think myself into an early death or something you know, like 
that six months to live, but with a view to living as long as 
possible but also being as kind as possible so that they’ve [my 
children] not got to think about what to do with me, I suppose. 
(ID=F5; Female; Focus group 1) 
 
 
So, that’s why I say it’s a difficult one because, in one way, I 
would like to know because there are things [you can do].  




The really negative aspects can be, well… helped a lot if you’re 
prepared…(ID=M1; Male; Focus group 1) 
Participants also touched on the capacity for the collection and sharing of genetic data to have 
the potential to benefit others, i.e. the ‘greater good’. There was a sense that participants were 
aware that the larger the database of genetic and phenotypic data, the more society can gain 





I think it would be selfish to… yes, not selfish but it’s better if we 
collect more so that we can help more people in the long 
run(…) you should just give your genome… (ID=F3; Female; 




I would agree with (…) [getting tested for the genetic variant 
for] Alzheimer’s and things because… especially if you had 
family so they would know, and you could help other people… 
people in the future who might have the same issue. (ID=M3; 
Male; Focus group 2) 
 
 
…they [society] always push forward scientific things which is 
the right thing to do.  It’s about survival and giving people 
options and choices and trying to help them. (ID=M3; Male; 
Focus group 2) 
 
 
3.7.5 Genetic exceptionalism: “DNA is different” 
A topic that came up frequently was the notion that genetic data is unlike other forms of data. 
Participants felt that genetic data forms a part of your personal identity in a way that other 
data does not, “it’s the coding of your own identity” (ID=M3; Male; Focus group 1). Participants 
also felt genetic data is more private than other types of data. This unsettling feeling 
contributed to concerns regarding data sharing. In addition, one woman spoke about being 
unable to pinpoint the exact reason as to why she felt uncomfortable with the idea of sharing 
her genetic data with the NHS, stating that it’s “just an intrusiveness you feel” (ID=F3; Female; 
Focus group 2). Again, there was a sense that this feeling of intrusiveness was tied to the 
notion that your genetic make-up forms a part of your personal identity which, in this 
participant’s eyes, would mean that “a lot of people [would] know exactly who you are”. 
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I just feel like you could be… probably found because it’s like 
your… makeup. (ID=F4; Female; Focus group 1) 
 
 
You know, DNA is quite a… it is a part of us, isn’t it?  It’s very… 
So, yes, but I can’t tell you really, really why but I think DNA is 
different. (ID=F3; Female; Focus group 2)   
 
 
I would be much more concerned about my genetic information 
[being leaked than my credit card information].  You can get 
back money, you can’t get back your y’know, it’s pretty much 
the personal bit of information you can have. (ID=M1; Male; 
Focus group 1) 
 
 
Well, it’s literally your DNA, your code and in essence, that is 
your identity so, it’s almost everything. (ID=M2; Male; Focus 
group 1) 
 
The question of whether we ‘should’, from a religious point of view, know our genetic data 
came up in both focus groups. This perception reflects the perceived uniqueness of genetic 
data, as it implies that genetic data should be considered untouchable. 
 
 Are we supposed to know [if you have a monogenic 
disorder]? (ID=M1; Male; Focus group 2) 
Do you mean from a religious point of view? (ID=F3; Female; 
Focus group 2) 




It’s a bit like playing God I guess. (ID=F3; Female; Focus group 
1) 
Facilitator: What do you mean by…? 
Respondent: So, you shouldn’t really know… you wouldn’t know 
about this advance in technology, but we do have it, so, I don’t 
know… (ID=F3; Female; Focus group 1) 
There are some things that are meant to be…(ID=F1; Female; 
Focus group 1) 
 
3.7.6 Charting possible futures 
Participants envisioned the ways in which genomic medicine may develop in the future. In 
particular, the potential for gene editing was discussed. Some participants noted that this could 
occur in more isolated events, such as the genetic modification of an individual’s children. 
Others spoke about a more wide-spread gene-editing agenda to create a better society. Whilst 
some participants gave the impression that they weren’t necessarily opposed to genetic 
modification, one participant’s use of the phrase “slippery slope” (ID=F4; Female; Focus group 
2) and the statement “I do have concerns about where that goes and how far it goes…like gene 
editing” indicated the perception that genetic modification is an undesirable consequence of 
genomic medicine.   
 
 
I think that [testing for carrier status] definitely opens up the 
realm for genetically modifying your kids in the future as well. 
(ID=M2; Male; Focus group 2) 
 
 
(…) if they were able to find out…say like the president’s 
genome code and then when they were looking to alter things 
in the future they could try and make people more pragmatic? 




In addition, participants spoke about their own ideas for how best to execute the delivery of 
genomic medicine. For example, one woman suggested that we should have an “opt-out service” 
for the donation of genomic data and that “you should just give your genome” (ID=F3; Female; 
Focus group 2). Another participant suggested that people’s genetic and phenotypic data could 
be collected after their death.  
 
 
So, like how they’re changing it next year so, you have to donate 
your organs, you don’t… it’s an opt-out service now, not an opt-
in, so, I think it should be like that and it should be… you should 
just give your genome… (ID=F3; Female; Focus group 2) 
 
 
Maybe when you’re born in the future, they’ll just take your 
code, your sequence and then, for the rest of your life they’ll just 





I’d be interested in it [getting your genome sequenced] but 
probably not whilst I was alive. (…) after you’re dead you could 
say, I’d like that to be done and then you could look through 
what I did with my life, my records and what I died of and if it 
made sense. (ID: M3; Male; Focus group 2) 
 
 
3.8     Discussion 
This section outlines my interpretation of the results in the context of other literature and the 
strengths and limitations of our study. Findings that I believe have implications for policy are 
discussed in Chapter 4.  
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3.8.1   Summary of main findings 
Participants showed an impressive awareness of both the potential benefits and drawbacks of 
genomic medicine. Participants displayed concerns that genetic test results could: cause 
anxiety and impede upon enjoyment of life in the present moment; lead to hypochondria or, 
worse, actually increase the severity of the illness; cause stress on their children or on their 
plans to have children; and lead to discriminatory behaviour from insurance companies, 
employers, the police, or potential romantic partners. However, participants also talked about 
the advantages of genomics. This included the potential for genetic test results to: empower 
people to live their life to the full; improve the ability of medical professionals to tailor 
treatments to improve outcomes; allow for physical, practical, and mental preparation for 
illness; and enable more informed decisions regarding whether or not to have children.  
 
In addition, participants talked about the cruciality of remaining anonymous throughout the 
genetic testing process. This tied in with their conversations surrounding the unique nature of 
DNA; participants felt that DNA conveys more personal information than other types of data. 
Discussions surrounding the invasiveness of genetic testing on privacy contributed to concerns 
surrounding the sharing of genetic data. Whilst participants acknowledged the likely benefits 
for science and society, participants also talked about the potential for a eugenics-like political 
regime. Participants also brought up the question of whether genetic research and genomic 
medicine is ‘playing God’. 
 
Finally, participants also put forward their own ideas for the delivery of genomic medicine. 
This included the proposal of an opt-out policy whereby, similar to organ donation, you are 
expected to donate your genomic data unless you choose not to. Another suggestion was that 
we should always donate our genomic and phenotypic data after death. 
 
3.8.2   Interpretation of findings in the context of other literature 
Our results mirror research from 20+ years ago that concluded the public see genetics as a 
‘double edged sword’ (Michie et al. 1995, pg. 250) – the participants expressed both concern 
and excitement about genomic medicine and its future.  
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Unlike previous studies (Bates et al. 2005; Stockdale, Cassell & Ford, 2018; Waters, Ball, & 
Gehlert, 2017), the participants were given information about both the current use and 
anticipated future use of genetic data in the NHS prior to the discussion. Nonetheless, 
participants voiced thoughts and opinions that have been found consistently throughout the 
literature. For example, participants’ concerns about the sharing of genetic data and access to 
genetic data by third parties have both previously arisen in other research (Hapgood et al. 
2004; Trinidad et al. 2010). Similarly, past studies have also discovered worries about genetic 
discrimination (Fox, 2002; Gottweis, 2002) and that genomic medicine is ‘playing God’ (Bates 
et al. 2005). Indeed,the participant’s perception of the potential benefits also echoed past 
research. For example, as in the Wellcome Trust’s (2016) research, participants felt that 
genomics will bring advantages to both healthcare and society. 
 
Despite discussing concerns about genetic discrimination from employers, insurance 
companies, and even potential romantic partners, participants did not discuss the possibility of 
racial discrimination, which has been found in previous research (Goldenberg et al. 2011; 
Peters, Rose, & Armstrong, 2004; Suther & Kiros, 2009; Middleton et al. 2018; Zimmerman et 
al. 2006). This may have been because the majority of participants were white, and people of 
colour are more likely to display such concerns (Bates et al. 2005). The Asian, biracial, and 
‘other ethnic group’ participants in my study may have felt outnumbered and unable to discuss 
such concerns. This demonstrates the need for research that provides a safe space within 
which people of colour can confidently explore and voice their thoughts and opinions. 
 
3.8.3   Strengths & limitations 
One of the challenges of qualitative research is the potential for the researcher’s opinions to 
bias the interpretation of the data. A strength of this study was that two researchers, with 
different research backgrounds, checked the coded topics leading to more rigorous analysis 
and discussion before a robust consensus could be reached on the topics for inclusion.  
Further, to my knowledge, this is one of the first qualitative studies in the UK to provide 
participants with some information about genetics in the NHS prior to the discussion. This 
allowed us to gather thoughts and opinions that are based on factual information regarding 
genomics as it exists now. However, this led to an expert-learner dynamic during the first focus 
group, and the participants asked the facilitators several questions. On reflection, this stalled 
the discussion and meant that there was less data on their personal opinion. Thus, a slight 
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alteration to the lead researcher’s introduction was made for the second focus group - the lead 
researcher stressed that, whilst the researchers could attempt to answer questions, the field of 
genomics is so new that it is unlikely they would know the full answer, and that they were far 
more interested in hearing the participants’ personal opinion.   
 
A weakness of this study was the recruitment method. The areas in which posters were put up 
were generally more affluent and more likely to attract the student population. Therefore, it is 
likely that the sample was biased by socio-economic status (SES) and education. Whilst we did 
not directly measure SES, education partly makes up the social class scale and a large majority 
of participants had at least a bachelor’s degree. In fact, all of the participants had completed 
education to GCSE level or above, whereas 27% of the UK population have no formal 
qualifications (Office for National Statistics, 2011). Whilst it is near impossible to obtain a 
representative sample in qualitative research of this type, and such detailed research is still a 
useful method to gauge the public’s views and guide future research, more effort to recruit 
participants from a range of backgrounds was needed in this study. Indeed, we are likely to 
have missed important perspectives from those with working class backgrounds and/or lower 
education levels. Therefore, future work should aim to recruit in a diverse range of areas that 
ensures as much as possible that people from all backgrounds are represented in research.  
 
On further reflection, another weakness was that the two groups of participants differed 
significantly from each other – one was a group of students, aged between 18–23 years, whilst 
the other group were all non-students and aged between 26–66 years. I originally made the 
decision to keep the two groups as they were because I thought younger students would feel 
more comfortable discussing potentially controversial opinions with their peers. On reflection, 
mixing the groups may have enabled a more varied discussion between the participants. The 
all-student group in particular may have benefited from this, as there was a tendency in this 
group to agree with one-another. This may have been due to a lack of confidence to challenge 
and contradict the status-quo amongst a group of similarly aged, younger peers. Further, two 
of the participants in first focus group were friends of mine. Whilst the impact of this is difficult 
to assess, our relationship is likely to have influenced their behaviour in the focus groups, 
which may have also impacted other participants’ perception of the group dynamic and in turn 
their responses. Future work should, whenever possible, recruit only people who are unknown 
to the researchers involved in the study to improve scientific integrity.  
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Further, given the monetary reimbursement, it is difficult to ascertain whether participants’ 
motivations were money or interest in genetics. However, due to the older age group in the 
second focus group (and thus higher likelihood to be employed) and the small amount offered 
(£10), it is plausible that these participants were more motivated by interest in genetics than 
by money. Again, these differences in motivation provide another reason as to why mixing the 
groups may have facilitated more varied discussions and may in fact be another reason why 
the younger participants in the first group were less motivated to disagree and have a varied 
discussion. 
 
3.8.4   Conclusions 
Overall, participants displayed nuanced understandings of the potential pros and cons of 
genomic medicine. This provides up-to-date evidence that members of the UK public see the 
use of genetic data in the NHS as delivering both great potential and great risk. This indicates 
that support for genomic medicine lies on a continuum - it is not as black and white as an 
individual being entirely pro or entirely anti genomic medicine. It is important that we use this 
information to address people’s concerns and to provide a realistic picture of the benefits of 
genomic medicine. 
 
3.9  Chapter summary  
This chapter explored the findings of my two focus groups, whereby participants were given 
information about genomic medicine and asked for their thoughts and opinions. My findings 
were similar to past research – participants discussed concerns such as discrimination and the 
detrimental psychological impact of results. They also showed an awareness that genomics has 
many potential benefits, such as enabling more accurate diagnoses and more effective 









Chapter 4: Discussion – policy 
recommendations & considerations for 
the NHS  
 
4.1 Chapter overview 
This chapter discusses the specific policy implications that have arisen from each study, as well 
as broader suggestions for the integration of genomic medicine into the NHS that have become 
apparent through the development of my thesis. This chapter concludes with a personal 
reflection on the future of genomic medicine. 
 
4.2 Policy recommendations:  does knowledge of genetics 
predict acceptance of genomic medicine? 
 
The first study in this thesis provided evidence against the traditional view of the deficit model 
(Sturgis & Allum, 2004) and offered a different interpretation of the importance of knowledge. 
I found that, independent of people’s actual knowledge of genetics, their perception of their 
knowledge was the most important predictor of their acceptance of genomic medicine. In other 
words, for the successful development and integration of genomic medicine into UK society, 
my findings suggest attempts to encourage confidence in science could be included as part of 
the broader initiative to improve public understanding and engagement with science through 
education. Importantly, this confidence must not come at the cost of their knowledge; it is vital 
to incorporate high quality education about genetics into school science. We can encourage 
public confidence through accurate and clear information and collaboration with the public. 
Also, I should further clarify that the objective of this work is not to improve attitudes to 
genomics at all cost, but rather to encourage both engagement with and understanding of 
genetics and genomic medicine by providing balanced and accurate information. Indeed, it is 
better that the public have concerns based on fact than positive attitudes based on 
misinformation and/or misunderstanding. My recommendations for policy are split into two 
categories below – the broader implications for communication with the public (section 4.2.1) 
 113 
and a more specific policy recommendation for improving public confidence in genetic 
knowledge (section 4.2.2).  
 
4.2.1 Broader implications for communication with the 
public: inclusion of initiatives to foster scientific engagement 
In addition to the passive dissemination of information to improve understanding of science, 
we could increase public participation in science initiatives and create and maintain an open 
dialogue with the public to foster more engagement with science. Indeed, given the 
interrelatedness of scientific understanding and scientific engagement, the following 
suggestions are aimed at developing successful strategies that improve upon both. For 
example, the educational charity ‘We The Curious’ focuses on removing boundaries between 
science and people (We The Curious, 2019). It allows visitors to ‘interact with exhibits and take 
part in experiments’ and is in the process of redesigning its venue based on questions from the 
people of Bristol on what makes them curious about the world. This style of approach has been 
found to increase the trustworthiness of researchers (Aitken, Cunningham-Burley & Pagliari, 
2016) and promote a harmonious collaboration between policy-makers and the public in 
decision-making processes (Rowe & Frewer, 2005). Similarly, I recommend scientists attend 
more public events and make genetics a more mainstream public engagement activity. 
Showing that genetics can be part of everyday life and that it is not confined to lab experiments 
and clinical settings should also help to promote trust in researchers, as well as increase 
knowledge and confidence in genetics.  
 
It would also be beneficial to improve our understanding of the social context in which 
genomic medicine will be delivered (Macintyre, 1995). This is important because the public 
reaction to genomics is as likely to be affected by the social environment in which the news is 
received as it is the perceived implications of genomics itself (Frewer, Howard & Shepherd, 
1995). Thus, as well as developing an understanding of the public’s confidence in their 
knowledge of science, we could improve our scientific understanding of the public. This 
includes understanding the public’s opinion, decision-making processes, and personal 
experience, as well as a thorough investigation of the pre-existing influence of social and 
cultural practices and institutions, socio-economic status and the media. For example, Frewer, 
Howard and Shepherd (1995) identified the cruciality of credible and trustworthy information 
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sources in shaping positive public reaction. Future research could explore the perceived 
trustworthiness of organisations such as Genomics England, UK Biobank and the NHS. This 
could be done by asking people who visit their websites to report their level of trust in that 
organisation on a given scale.  
 
4.2.2  Specific policy recommendations: how can we increase 
public confidence in genetic knowledge? 
 
4.2.2.1 Promotion of successful and positive experiences with genetics and 
genomic medicine 
Research has demonstrated that one of the most powerful approaches to improving confidence 
with new technology is the acquirement of personal experiences that are successful (Ertmer & 
Ottenbreit-Leftwich, 2010). Therefore, we suggest that science initiatives should encourage the 
public to apply genetic knowledge in a way that is both useful and correct. For example, they 
could highlight that anyone who has looked at their family history of disease has successfully 
applied the rules of genetics. Future research could include an experimental study to explore 
the effect of acknowledging such a positive experience on the acceptance of genomic medicine.  
Similarly, another study discovered that confidence in technology also increases when people 
observe how that technology enables others’ success (Ottenbreit-Leftwich, 2007). Accordingly, 
we propose that we should promote discussions about instances where genomic medicine has 
had a positive impact to the NHS, society, or science. For example, ‘success stories’ that reflect 
on a specific individual experience, scientific discovery, or public benefit. In fact, research 
shows that genetic technology is more accepted if it is seen to be useful (Gaskell et al. 2000), 
necessary (Frewer, Howard & Shepherd, 1995), or for a specific purpose (Harlander & Roller, 
2012). Therefore, we recommend that genomic ‘success stories’ could draw upon the times in 
which the experience with genomic medicine showcased these three characteristics. However, 
we do not want to lure people into a false sense of security. All ‘success stories’ should give a 
balanced account of the ups and the downs, to ensure that the public have an informed 
understanding and realistic expectations of genomic medicine.  
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4.2.2.4 Summary of policy recommendations: does knowledge of 
genetics predict acceptance of genomic medicine? 
In summary, attempts to increase the public’s confidence in their genetic knowledge could be 
included as part of the larger initiative that aims to improve public scientific understanding. 
Generally speaking, this could include focussing on public engagement activities that break 
down the barriers between science and the public. More specifically, I recommend increased 
communication of ‘success stories’ in genetics. However, these initiatives should not come at 
the cost of knowledge. We can improve both confidence in knowledge and actual knowledge 
through increased communication of accurate and reliable information in a way that increases 
engagement with, as well as understanding of, science.  
 
4.3 Policy recommendations: qualitative study – an 
exploration of an informed public’s opinion of genetics in 
healthcare 
Our qualitative study provided evidence that members of the UK public, after being informed 
about the history, current state, and future hopes of genomic medicine, see genomics as 
representing both great potential and great risk. In this section I have focussed on findings that 
hold implications for policy and the NHS.    
 
4.3.1 Third party access & the importance of anonymity 
Participants discussed the importance of maintaining anonymity and shared their concerns 
about third party access to their data. This finding is reflected in my quantitative study, 
whereby participants displayed the highest levels of concern about who would have access to 
their data once it is stored in an NHS database (section 2.4.6.5.3). This finding is not new - 
previous research has found similar concerns multiple times (Howe et al. 2018; Majumder, 
Cook-Deegan & McGuire, 2016; Open Data Institute, 2018). Therefore, perhaps these concerns 
have not been addressed sufficiently so far – we should be doing more to address them if 
people continue to be concerned. For example, UK residents should be given more detailed 
information about how exactly genetic data is anonymised, and which organisations will be 
allowed to access it. Information regarding the security of genetic data under GDPR, the Data 
Protection Act (2018) and the Cyber Security Programme in the NHS, as discussed in section 
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1.7.2.5, could be made more readily available to the public. However, as previously discussed, 
this information should be communicated in an accurate and unbiased way, with the aim to 
inform and not persuade. Concerns regarding illegal access to and use of data are legitimate 
fears and information of this type is unlikely to address or reduce them. Therefore, public 
concerns should be listened to in a way that offers relevant and useful information regarding 
legislation when necessary but does not lure people into a false sense of security when 
concerns are outside of the control of such legislation. Further, future research would need to 
explore how we can strike a balance between not overloading patients with information but 
giving them enough information so that they can make an informed decision. This may involve 
having extra information readily available for those who want more detail about data storage 
and security.  
 
4.3.2 Genetic exceptionalism 
Interestingly, unlike my quantitative results that revealed similar feelings of comfort towards 
different types of data being stored by the NHS, my qualitative study provided evidence of 
‘genetic exceptionalism’. Participants felt that DNA was different as it has deeper links with 
personal identity. My exploration of genetic exceptionalism in the quantitative study was 
limited to three questions that compared feelings towards genetic, mental and sexual health 
data and may have been confounded by the high level of trust people have in the NHS (Ipsos 
MORI, 2013). Contrastingly, the qualitative study did not ask for the same comparisons and 
allowed for a more open discussion. This difference in the conclusions between the two studies 
also demonstrates that qualitative research can offer a deeper insight into certain phenomena, 
particularly complex areas such as genomic medicine. This finding also offers some insight into 
the mechanism behind genetic exceptionalism – the idea that your genome is you in ways that 
other data is not, opens up the possibility for unwanted identification and thus more 
personally harmful misuse of this kind of data. This reinforces the importance that people 
place on anonymity as mentioned above. We should aim to be transparent about how genomic 
data is de-identified, as well as continuing to employ strict rules on who gets access to that 
data. Overall, it is clear that people want privacy but, given the difficulties associated with 
completely anonymising genetic data and the ever-present possibility of illegal access to data, 
the delivery of total privacy in a way that satisfies the public’s wants is unlikely to be realised.  
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4.3.3 The importance of genetic counsellors 
Participants also displayed particular concern for the impact of genetic test results on their 
mental health. Not only were participants concerned that genetic tests could cause them 
anxiety, but they talked about the potential for the knowledge of your genetic results to 
actually make the illness worse This highlights the importance of genetic counsellors, and 
again ties in with the proposal from my quantitative study that suggested both the existence 
and role of genetic counsellors should be emphasised in our discussions with the public 
(section 4.2.2.3). Genetic counsellors provide advice and support both before and after getting 
a genetic test result, but nearly half of the participants (43.7%) believed that meetings with 
genetic counsellors are only for those who have discovered they have a genetic predisposition 
for disease. Therefore, we should emphasise that these meetings can occur at any time 
throughout the genetic testing process, including before the patient has even decided whether 
or not to get a genetic test. Knowing that genetic counsellors are available to help with the 
decision may help to ease the anxieties regarding the impact on mental health, as well as 
hopefully encouraging patients to also seek expert advice and information from a genetic 
counsellor if required.  
 
However, the NHS are planning to mainstream genomics more and more in the coming years, 
and non-genetic specialist doctors will therefore be expected to order, interpret and deliver 
genetic results. This may result in fewer patients having discussions with genetic counsellors. 
My results suggest that perhaps there should be a concerted effort to recruit more genetic 
counsellors, so that non-genetic specialist doctors could run their decisions past a genetic 
counsellor before delivering them to a patient. Alternatively, some genetic counsellors could be 
employed for the specific purpose of interpreting results before they are sent to clinicians. 
Results that are complex, or likely to require extensive emotional or practical support, could be 
flagged up by genetic counsellors to ensure the highest level of patient care. Of course, 
recruiting and training more genetic counsellors would be expensive. Whether this is viable in 
our cash-and-time-poor NHS is difficult however, given the consequences of misinterpreting 




4.3.4 The public are keen to get involved with the 
development of genomic policy 
Participants put forward their own proposals for how the future of genomic medicine could 
look. For example, one participant suggested an opt-out method regarding the donation of 
genomic data to research. This method has been posited to decrease the burden of obtaining 
voluntary participation from large numbers of patients whilst allowing these patients to 
exercise their right to not participate should they wish to do so (Brothers et al. 2013). Research 
has explored the effectiveness of such an opt-out system when collecting blood samples for 
clinical use that would otherwise be discarded (Roden et al. 2008). This included linking the 
patients’ genomic data to their electronic medical records. The researchers discovered that this 
approach can generate larger datasets with increased diversity of phenotypes. So, this 
suggestion from one of the participants indicates the public are not only keen to discuss ideas 
for the development of genomic policy, but that the ideas they put forward can be insightful 
and have great potential. Therefore, we could increase the number of discussions policy-
makers and researchers have with the public. An excellent example of such a discussion was 
the recent ‘Public dialogue on genomic medicine’ (Ipsos MORI, 2019), that explored the 
public’s opinion on how the NHS should mainstream genomics. This was a discussion between 
the public and people who work for various organisations such as Genomics England, NHS, 
Wellcome Trust, Department of Health and Social Care, and researchers from UK universities. 
This research, as well as the research in this thesis, is of critical importance for the NHS and UK 
Government because it expresses the opinions of the public and could be used to inform future 
policy.  
 
4.3.5 Knowledge is power 
Interestingly, there were wide discussions about the potential for genomics to enable a more 
fulfilling life in which you treasure your relationships and make more informed decisions 
regarding your health. Whilst this positive approach may be effective for some people, it is vital 
that we ensure that the public and patients are aware of the current limitations of genetic 
testing. Genetic results may, in fact, not reveal anything of use due to low prediction value for 
complex disease and our limited knowledge of genomics. People must be given accurate 




4.3.6 Summary of policy recommendations: qualitative study 
– an exploration of an informed public’s opinion of genetics in 
healthcare 
To summarise, there should be increased communication about the current rules and 
legislation surrounding the security and storage of genetic data; we need to be transparent 
about how genetic data is anonymised and which organisations have access to it. Further, the 
NHS should consider investing in the recruitment of more genetic counsellors. Also, the public 
display enthusiasm for discussions about genomics and have insightful ideas that should be 
explored with further research.  Finally, when communicating with the public, it is crucial that 
we are clear about the limits of our genetic knowledge to avoid the development of unrealistic 
expectations.  
 
4.4 Future analyses & research 
Below are some specific ideas for further analyses of the current dataset in the quantitative 
study.  Also, both studies in this thesis had broader implications for research into genomic 
medicine. 
 
4.4.1 Measure of confidence in knowledge   
First, it is important to recognise the limitations of the methodology and analysis in the 
quantitative study.  Participants’ confidence in genetic knowledge was based on only 4 
questions. In contrast, combined knowledge was based on a total of 29 questions that 
measured knowledge on an array of genetic topics. Therefore, it may be that specific aspects of 
knowledge were indeed related to acceptance of knowledge, but that this relationship was 
masked by other specific aspects of knowledge that were not related to acceptance. So, 
breaking down the larger and more general combined knowledge measure into smaller, more 
specific aspects of genetic knowledge may uncover associations that had previously been 
masked. Indeed, a total of 13 questions were removed from the final measures of biological and 
clinical knowledge due to a lack of internal reliability. Breaking down the combined measure 
into these specific aspects of genetic knowledge, such as family relatedness and heritability, 
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may offer some useful insight into the lack of inter-relatedness between these items and the 
final items. 
 
Another way of doing this could be to focus on the themes within the four questions in the 
perception of knowledge measure. These specifically asked about participants’ confidence 
regarding their knowledge of the terms ‘DNA’, ‘human genome’, ‘genetically modified’, as well 
as their self-reported understanding of the ethical issues raised in genetic research. Thus, 
future analyses of this data set could include the creation of four clusters from items in the 
combined measure:  understanding of DNA, understanding the human genome, understanding 
genetic modification and demonstrating an awareness of ethical issues. Multiple regression 
analyses using these four clusters as individual predictor variables would indicate their ability 
to predict acceptance of genomic medicine. Indeed, given that confidence in these four aspects 
of knowledge predicated acceptance of genomics, it may be that actual knowledge of these 
features of genetics is associated with acceptance. If so, perhaps we should focus on 
encouraging knowledge of and engagement with specific parts of the broad subject matter that 
is genomic medicine. It would also be interesting to explore the relationship of these new 
predictor variables with each corresponding confidence measure. For example, exploration of 
the correlation between confidence in knowledge of DNA and actual knowledge of DNA would 
enable a more valid conclusion as to whether the public are accurate in estimating their genetic 
knowledge.  
 
4.4.2 Exploration of negative correlation between being a parent 
and knowledge 
In the past, researchers have hypothesised that parents would have higher genetic knowledge 
than people with no children, given that they may actively seek out genetic information that 
may be relevant for their child/children (Chapman et al. 2019). However, this same research 
actually revealed no significant difference in knowledge between those who have children and 
those who do not. In the present study, there was a negative correlation between being a 
parent and both actual and perceived knowledge of genetics. Further analysis of this finding 
could include multiple regression that controls for the effects of age (age was also negatively 
correlated with both measures in our study) as parents are likely to be older than people with 
no children. Age may have confounded the association given that it is linked to the length of 
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time since people were in education. Also, as genetics and genomic medicine are becoming 
more mainstream, it is likely that there has been an increase in the amount of genetics taught 
at school. Therefore, older people who went to school before this surge in genetics education 
may have a lower level of genetic knowledge. This would be interesting to explore as it could 
indicate whether educational initiatives should include a concerted effort to target those of an 
older age.   
 
4.4.3  Future research should include a measure of religious 
beliefs 
The finding in my qualitative study that participants were concerned that genomics was 
‘playing God’ served as a reminder that I should have included a measure of religious beliefs in 
my quantitative study. Indeed, Allum et al. (2014) found that Catholics are less supportive of 
genetic testing on unborn babies than those without religious beliefs, and other research has 
found that atheist participants displayed higher genetic knowledge than their Christian 
counterparts (Chapman et al. 2017). Further, Allum et al. (2014) found that religion can act as 
a ‘perceptual filter’ and affect the way in which scientific knowledge affects attitudes to genetic 
testing, i.e. despite their finding that more knowledgeable participants were more supportive 
of genetic testing, this relationship was reversed if the participants were also highly religious. 
This finding is particularly relevant to my quantitative study because the potential presence of 
religious beliefs may have negatively affected the strength of the relationship between 
knowledge and acceptance. Future research should include a measure of religious beliefs to 
explore whether it has an effect on the relationship between knowledge and acceptance.   
 
4.5  The future of genomic medicine: a personal reflection 
I have spent this year reading widely about the history, current state, and future of genomic 
medicine in the UK. In addition, I have attended the Festival of Genomics in London and the 
European Society of Human Genetics conference in Gothenburg and have collaborated with the 
West of England Genomic Medicine Centre.  
It has become clear that without the careful consideration and exploration of public opinion 
and concerns, we run the risk of missing the full range of opportunities to advance medical 
 122 
frontiers on both a national and global level. Public trust and support is important in order to 
secure a successful future for genomics. However, whilst the NHS and policy-makers should 
continue to address the concerns that were discussed in the focus groups, this should be 
conducted in an unbiased way that aims to provide accurate and relevant information that 
helps people come to their own conclusion, i.e. the provision of this information is to inform 
and not persuade. Also, some concerns, such as illegal use of genetic data or accidental leaking 
of genetic data, are unlikely to be addressed with the provision of information regarding the 
law and/or legislation surrounding genetic data. The majority of concerns such as these should 
simply be listened to and recognised as serious anxieties. 
Also, findings regarding the importance of confidence in genetic knowledge in chapter 2 should 
be analysed further, e.g. breaking down the combined knowledge measure to tap into more 
specific aspects of genetic knowledge and their influence on acceptance. Future research 
should include a personality measure to control for the effects of general confidence and high 
self-esteem, as well as recruiting a more diverse sample in terms of SES, education, and 
ethnicity.  Indeed, the recent decision by the government to not charge people for voluntary 
genomic testing due to fears over creating a two-tiered healthcare system reflects an inclusive 
approach to healthcare that we should continue to uphold in research.  
Overall, we are at the beginning of the implementation of genomic medicine into routine care. 
It is an incredibly exciting time for genomics; it has been a privilege to conduct research into 
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Appendix 1    Screenshot of online ethics application and approval for 































1. How old are you? Please indicate your age in years. 
______ 
 




• Prefer not to say 
 
3. To which ethnic group do you identify most? 
• White/White British 
• Asian/Asian British 
• Black/African/Caribbean/Black British 
• Biracial/Biracial British 
• Other ethnic group 
• Prefer not to say 
 
4. Do you have any children? 
• Yes 
• No 
• Prefer not to say 
 
5. What is the highest degree or level of school you have completed or are currently enrolled 
in? 
• No schooling completed 
• GCSEs or equivalent 
• A Levels or equivalent 
• Trade/technical/vocational training or equivalent 
• Master’s degree or equivalent 
• Professional training/Graduate scheme or equivalent 
• Doctorate degree or equivalent 
• Prefer not to say 
 
 
6. When were you last taught about genetics? 
• Still studying genetics 
• 1-5 years ago 
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• 5-10 years ago 
• 10-20 years ago 
• 20+ years ago 
• Have never been taught about genetics 
• Prefer not to say 
 
7. Do you come across genetics in your workplace? 
• Yes  
• No  
• I am not in paid employment 
• Prefer not to say 
 
 
[Experience with genetic testing] 
 
1. Before beginning this survey, had you heard of genetic testing? 
• Yes 
• No 
• Prefer not to say 
 
2. Have you or anyone close to you ever had a genetic test done by a doctor? 
• Yes 
• No 
• Prefer not to say 
 
3. Have you ever used an online genetic test to assess your genetic health risk? 
• Yes 
• No 
• Prefer not to say  
 
4. Have you ever used an online genetic test to assess your ancestry? 
• Yes 
• No 
• Prefer not to say  
 
 
[Biological knowledge of genetics] 
 
Below are some questions about genetics and their role within the body. Please answer 
these questions to the best of your ability.  
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1. Which of the following is TRUE:  
• It is the mother’s genes that determine the sex of the child1 
• By eating a genetically modified fruit, a person’s genes could also become modified1 
• Humans share approximately 99% of their DNA with each other1 
 
2. Which of the following is FALSE: 
• By eating a genetically modified fruit, a person’s genes could also become modified1 
• The cloning of living things produces genetically identical copies1 
• All plants and animals have DNA1 
 
3. Which of the following is TRUE: 
• More than half of human genes are identical to those of mice1 
• An individual who is a carrier of a genetic disease will develop the disease as they age  
• Genes are always more important for how you look than how you behave  
 
4. Which of the following is FALSE: 
• Your genetic make-up can influence the way that you respond to medical interventions2 
• Cancer can be caused by both inherited genetic mutations or mutations that are 
acquired throughout the lifetime2 
• A ‘dominant trait’ is a trait that is most popular in a single population 
 
(5. Which of the following is FALSE: Excluded as there is more than one correct answer) 
• Environmental factors, such as cigarette smoke, can affect gene activity3 
• When someone says something is “epigenetic” it means that you can inherit changes in 
gene activity without inheriting changes in the genes3 
• Most of the human genome consists of genes that code for proteins3 
 
6. Which of the following is TRUE: 
• Traits with higher heritability are more difficult to change4 
• Interventions should be targeted to traits influenced by the environment4 
• Environmental interventions can be used to mitigate genetic risk4 
 
7. Which of the following is FALSE: 
• DNA is contained in the nucleus of the cell4 
• DNA stands for Deoxyribonucleic acid4 
• DNA uses a four letter code4 
• The bases of DNA are AUGC4 
 
Are the following statements true or false? 













Please answer the following questions to the best of your ability. 
 







12. The word ‘heritability’ means…4 
• The proportion of the variation in the physical composition of a population accounted 
for by genetic variation 
• The proportion of a physical composition that is passed on to the next generation 
•  The proportion of a person’s characteristic that is accounted for by genes 
• The proportion of genes that are important for the development of a characteristic 
 







14. What is a genome?5 
• A sex chromosome  
• The entire sequence of an individual's DNA 
• All the genes in DNA  
• Gene expression  
 
15.  What is the main function of all genes?5 
• Storing information for protein synthesis 
• To provide energy to the cell  
• To clear out waste from the cell  
 156 
• To repair damage to a cell  
 
16. Approximately how many genes does the human DNA code contain?5 
• 2,000  
• 1 million  
• 3 billion  
• 20,000 
 
17. The DNA sequence in two different cells, for example a neuron and a heart cell, of one 
person, is:5 
• Entirely different  
• About 50% the same  
• More than 90% the same  
• 100% identical  
 
18. -Non-coding DNA describes DNA that:5 
• Is removed when passed from parent to offspring  
• Does not lead to the production of proteins 
• Is non-human DNA  
• Is not composed of nucleotides  
 
 
19 - 22. On a scale of 0-100 how important do you think genetic differences are between 
people in explaining individual differences in the following traits (with 100 = only genetic 




Please read the following scenarios and select the answer you believe to be correct. 
 
23. A doctor tells a couple that they’ve got a one in four chance of having a child with genetic 
disease...6 
• ...if their first three children are healthy, the fourth will have the illness  
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• ...if their first child has the illness, the next three will not 
• ...each of the couple's children will have the same risk of suffering from the illness 
• ...if they have only three children, none will have the illness 
 
  
24. A patient is told that the results of their genetic test indicate they are at increased risk of a 
particular disease. Consequently, they decide to engage in healthier behaviours, such as 
exercising regularly and eating a more balanced diet.  
• ...their increase in healthier behaviour will have no effect on their likelihood of 
developing the disease, because their genetic test indicates they will definitely develop 
the disease at some point 
• ...their increase in healthier behaviour will definitely decrease their likelihood of 
developing the disease, because the effect of the environment will always override the 
influence of their genes 
• ...their increase in healthier behaviour may lead to a decrease in their likelihood of 
developing the disease, because the way their genes work can be altered by their 
environment 
 
25. The Smith family consists of a mother, father, a pair of identical twins, and a daughter.   
• ...the parents each share 50% of their DNA with each of their children, the identical 
twins share 100% of their DNA with each other, and the daughter shares 50% of her 
DNA with each member of the family 
• ...the parents each share 50% of their DNA with each of their children, the identical 
twins share 50% of their DNA with each other, and the daughter shares 50% of her DNA 
with each member of the family 
• ...that the parents each share 50% of their DNA with each of their children, the identical 
twins share 100% of their DNA with each other, and the daughter shares 100% of her 
DNA with each member of the family 
• ...the parents each share 100% of their DNA with each of their children, the identical 
twins share 100% of their DNA with each other, and the daughter shares 50% of her 
DNA with each of the twins 
 
[Perception of genetic knowledge] 
 
1. When you hear the term DNA, how would you rate your understanding of what the term 
means? 1 
• Very good  
• Good  
• Some understanding  
• Heard the term, but little understanding of what it means  
• Have not heard the term  
• Don’t know  
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2. When you hear the term ‘human genome’, how would you rate your understanding of what 
the term means? 2 
• Very good  
• Good  
• Some understanding  
• Heard the term, but little understanding of what it means  
• Have not heard the term  
• Don’t know  
 
3. When you hear the term GM or ‘genetically modified’, how would you rate your 
understanding of what the term means?3 
• Very good  
• Good  
• Some understanding  
• Heard the term, but little understanding of what it means  
• Have not heard the term  
• Don’t know  
 
4. Please indicate how much you agree or disagree with the following statement…I feel I have a 
good understanding of the ethical issues raised by genetic research4 
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
 
[Clinical knowledge of genetics in healthcare] 
 
Before you begin the next section, please bear in mind that the phrase 'genetics in 
healthcare' refers to the use of an individual's genetic information to inform their 
clinical care.  
  
This next section includes statements about the current state of genetics in UK 
healthcare. Please indicate whether you believe them to be true or false. 
 
1. Using an individuals’ genetic code, we are currently able to predict whether an individual 
will develop every single disease known to the medical community 




2 There are many common diseases where the study of genetics can show the road to better 
treatment1 
• True  
• False 
 
3. The use of genetics in healthcare can mean that expensive drugs are only given to those who 
will benefit from them1  
• True  
• False 
 
4.  It is against the law for a doctor to not disclose a patient’s genetic test results to their close 
relatives as, given their genetic relatedness, the results may also concern them2   
• True  
• False 
 
5. Currently, treatment for cancer can include a genetic diagnosis to show if a tumour might 
respond to a certain treatment3 
• True  
• False 
 
6. The use of patients’ genetic data to deliver targeted therapies is already changing people’s 
lives1  
• True  
• False 
 
7. A patient will only speak with a genetic counsellor if their genetic test result indicates they 
have a genetic predisposition to a disease4 
• True  
• False 
 
8. Through a number of genetic testing techniques, it is possible to detect genetic abnormalities 
in an unborn child5 
• True  
• False 
 
9. The rapidly expanding role of genetics in many healthcare decisions is already increasing the 
demand for qualified genetics professionals1 




10. Currently, the NHS has every individual patient’s genetic code stored on their database  
• True  
• False 
 
11. At present in the UK, newborn infants are tested for certain genetic traits6 
• True  
• False 
 
12. How soon is the NHS planning to include genetics in routine healthcare?7 
• In the next 10 years 
• In the next 25 years 
• In the next 50 years 
 
The next 4 questions are aimed at exploring your more general awareness of the use of 
genetics in healthcare. Please answer these questions as truthfully as possible.  
 
13. How much have you read or heard about genetic tests that predict the likelihood that a 
person will develop certain genetically influenced diseases or conditions, such as heart disease, 
cancer and Alzheimer's?8 
• Quite a lot  
• Some   
• Not much  
• Nothing at all 
• Don’t know  
 
14. Before beginning this survey, were you aware of the use of genetics in healthcare? 
• Yes 
• No 
• Prefer not to say 
 
15. Have you heard of the 100,000 Genomes Project? 
• Yes 
• No 
• Prefer not to say 
 
16. Have you heard of Genomics England? 
• Yes 
• No 
• Prefer not to say 
 




• Prefer not to say 
 
[Acceptance of genetics in healthcare] 
 
Before you begin this final section, please read the information below from Genomics England and 
the NHS regarding the current status of genetics in healthcare1,2. You can refer back to this 
information at any point when answering the next set of questions. 
  
 In 2012, the UK Government set out to gather 100,000 complete sets of genetic information 
(genomes) from patients with cancer or a rare disease (using a process called 'whole genome 
sequencing'). On the 5th December 2018 they reached their target, and now the NHS will provide 
a whole lifetime of medical records from each participant of the project and link it to their genetic 
information. This will help us to tease apart the complex relationship between our genes, what 
happens to us in our life, and illness.  
  
The NHS is the first healthcare system in the world to do this on such a large scale. This 
information will provide a unique research database, thus enabling a powerful learning system 
able to provide better outcomes for patients.  
  
Now, the UK wants to reach a target of 5 million genomes by 2023/24. To help reach this target, 
patients with a rare disease or cancer will now begin to be offered whole genome sequencing by 
the NHS as part of routine care. For these patients, this will enable more comprehensive and 
precise diagnosis and access to more personalised treatment. Also, healthy people in England 
will also be given the option to undergo whole genome sequencing, however the test will cost 
them (predicted to be hundreds of pounds).  
  
 Overall, the aim is to create a new genetic medicine service for the NHS - transforming the way 
people are cared for. For example, patients may be offered a diagnosis where there wasn't one 
before, or may be able to make more informed decisions regarding their treatment.  And in time, 
there is potential for the development of new and more effective treatments. NHS England states 
that this approach to medicine takes greater account of people’s genetic differences, rather than a 
“one-size-fits-all approach to the treatment and care of patients with a particular condition”. 
  
1. First, please indicate how optimistic you are about the possibility of medical advances as a 
result of genetic research3 
1. Not at all optimistic   
2. Not too optimistic  
3. Somewhat optimistic   
4. Very optimistic  




Now, please indicate how much you agree with the following statements regarding 
genetics and the use of genetics in healthcare.    
 
2. If I was told that knowledge of my genetic data may improve the effectiveness of a medical 
intervention that I required, I would not hesitate to have my genetic data tested 
• Strongly agree   
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
 
3. The use of genetic data to inform medical decisions is overly intrusive  
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
4. I am concerned about who will have access to my genetic data once it is stored within an 
NHS database 
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
 
5. The benefits that the use of genetics in healthcare will bring to our healthcare system far 
outweigh any potential downsides  
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
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6. I do not welcome the notion of genetics in healthcare because insurance companies will ask 
for genetic information to decide how at-risk one is for ill health, which may increase the price 
of health insurance  
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
7. If my genetic data was included in research which eventually led to the development of a 
medical drug, I would not be happy for a commercial company to profit from the selling of this 
drug 
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
8. I would be more concerned about my genetic data being leaked than my credit card 
information4 
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
9. Family members share many genetic traits and may have the same genetic 
abnormalities associated with disease. Therefore, all immediate family members must give 
consent before an individual in that family gets a genetic test for medical reasons5 
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
10. I believe that my destiny is written in my genes6 
• Strongly agree  
• Moderately agree  
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• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
 
11. I do not trust the healthcare system in the UK because it might misuse genetic data 
obtained from patients6 
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
 
12. I feel suspicious about genetic studies for the improvement of health: hidden 
political/economic agendas may be behind them6 
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
 
13. Scientific development, including the research in genetics, is essential for improving 
people’s lives6 
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
14.  Preventing health problems is preferable to curing health problems 
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
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The next 3 questions consider the various types of medical data that can be stored by 
the NHS. Currently, the NHS keeps medical records which will include keeping track of 
any appointments you may have had with your GP. Please indicate how much you agree 
with the following statements.7 
 
15.  I would feel uncomfortable with the possibility for the NHS to have my genetic data on 
record 
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
16. I feel uncomfortable with the possibility that the NHS have my sexual health data on record 
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
17. I feel uncomfortable with the possibility that the NHS have my mental health data on record 
• Strongly agree  
• Moderately agree  
• Slightly agree  
• Slightly disagree  
• Moderately disagree  
• Strongly disagree   
 
18. Now, please indicate which statement you agree with most:8 
• For me, DNA information is the same as any other medical information, like blood 
pressure or blood sugar levels 
• For me, DNA information is different to other medical information because, for example, 
it tells us how we are related to other people 
• I’m not sure 
 
19. Finally, imagine yourself in the following scenario. You have an opportunity to have a 
genetic test that may reveal that you are going to develop a condition that currently does not 
have any medical treatment options. Which statement do you agree with most?9 
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• Knowledge is power: I would rather have the genetic test, so that I can prepare 
financially, emotionally, and practically if I am found to have a genetic variant that will 
lead to an (currently) incurable disease 
• Ignorance is bliss: I would rather not have a genetic test, because if I am found to have 
a genetic variant that will lead to an (currently) incurable disease I would worry about 
it too much to be able to carry on enjoying my life to the full 
• I’m not sure 
 
That is the end of the survey - thank you for your time. 
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Appendix 3.1    First pilot results of biological knowledge of genetics.      





























































































































Appendix 3.4    Breakdown of the recruitment method.      
 
Response Organisation/Person Type of contact Means of 
distribution 
Distributed 
(n = 23) 
Dr Anna Middleton Academic Via Twitter 
Union UCL BME 
Students’ Network 
Student group Distributed 
via  
Facebook  
SU BME Network Student group Distributed 
via Facebook  
Teacher at primary 
school 




University of Bristol Academic Distributed 
via Twitter 
Bristol Alumni Academic Distributed 
via LinkedIn 
Alumni page 
The Academic Midwife  Academic Distributed 
via Facebook 
VCS Cymru Volunteering group Distributed 
via email 






disAbility Cornwall & 


















































NoFitState Cardiff Circus company Distributed 
via email 




CoppaFeel! Personal Distributed 
via email 











(n = 11) 




Parkinson’s UK Charity N/A 









MS Society Charity N/A 
Avon Organic Group  Community/Volunteering 
group 
N/A 




Friends of the Downs 






(n = 356) 
Transition Bath Community/Volunteering 
group 
N/A 
 The New Somerset 




 Bath Area Play Project Community/Volunteering 
group 
N/A 
 Julian House Community/Volunteering 
group 
N/A 














 St John’s Ambulance Community/Volunteering 
group 
N/A 
 The Carers’ Centre 















 Doing Good Leeds Community/Volunteering 
group 
N/A 





 Leeds Mencap Community/Volunteering 
group 
N/A 










 Age UK Plymouth Community/Volunteering 
group 
N/A 
 The zone Plymouth Community/Volunteering 
group 
N/A 





 NCVO Volunteering Community/Volunteering 
group 
N/A 













 Dorset City Council Community/Volunteering 
group 
N/A 















 Brendon Care Community/Volunteering 
group 
N/A 
 Books on Wheels Community/Volunteering 
group 
N/A 
 Bournemouth Council 


















 Contact the Elderly Community/Volunteering 
group 
N/A 





 Dorset Community 




 Stroke Association Community/Volunteering 
group 
N/A 





 Elf Exeter Leukaemia Community/Volunteering 
group 
N/A 
 Exeter City Farm Community/Volunteering 
group 
N/A 
 Devon Wildlife Trust Community/Volunteering 
group 
N/A 





 Devon County Council Community/Volunteering 
group 
N/A 
 Volunteer Cornwall Community/Volunteering 
group 
N/A 





 Cornwall Social Group  Community/Volunteering 
group 
N/A 





 Team Green! Community/Volunteering 
group 
N/A 






 Armed forces and 




 A Band Of Brothers Community/Volunteering 
group 
N/A 
 Bodmin Day Centre Community/Volunteering 
group 
N/A 







 C Fylm Community/Volunteering 
group 
N/A 





 Centre Of Pendeen Community/Volunteering 
group 
N/A 









 Cornwall Tech Jam – 














 Hayle Day Care Centre Community/Volunteering 
group 
N/A 





 Mens Pub Lunch 










 Park View Community/Volunteering 
group 
N/A 
 Young farmers club Community/Volunteering 
group 
N/A 





 Royal Voluntary 










 Pavillion on the Park Community/Volunteering 
group 
N/A 





 Community First  Community/Volunteering 
group 
N/A 
 UNIT 12 Community/Volunteering 
group 
N/A 







 Carroll Centre Community/Volunteering 
group 
N/A 






 John Pounds Centre Community/Volunteering 
group 
N/A 

























 Hayling Island  Community/Volunteering 
group 
N/A 





















 St Joseph’s Hospice  Community/Volunteering 
group 
N/A 





 The Sock Mob  Community/Volunteering 
group 
N/A 






 Hands on London Community/Volunteering 
group 
N/A 
 City of London Community/Volunteering 
group 
N/A 






 Maiden Lane 










 Coram’s Field Community/Volunteering 
group 
N/A 
 Self Management UK Community/Volunteering 
group 
N/A 
 Alford House Community/Volunteering 
group 
N/A 





Kings corner project Community/Volunteering 
group 
N/A 
 EMCA Community/Volunteering 
group 
N/A 





 Sky Way London Community/Volunteering 
group 
N/A 
 Eastside Community/Volunteering 
group 
N/A 










 Highbury Roundhouse  Community/Volunteering 
group 
N/A 





 Elizabeth House Community/Volunteering 
group 
N/A 










 Caius House Youth Community/Volunteering 
group 
N/A 






 TowerProject Community/Volunteering 
group 
N/A 
 Copleston Centre Community/Volunteering 
group 
N/A 
 The Space Community/Volunteering 
group 
N/A 
































 Islington Arts Factory Community/Volunteering 
group 
N/A 










 Poplar Harca 20 Community/Volunteering 
group 
N/A 
















 Alpha Grove Community/Volunteering 
group 
N/A 
 Peter House Centre  Community/Volunteering 
group 
N/A 
 Brand New Start Community/Volunteering 
group 
N/A 
 St Faith’s Centre Community/Volunteering 
group 
N/A 
 Postive Network Community/Volunteering 
group 
N/A 
 AccessAble Community/Volunteering 
group 
N/A 
 Global Woman.co Community/Volunteering 
group 
N/A 
 St Mary’s Tottenham Community/Volunteering 
group 
N/A 
 Aston Mansfield Community/Volunteering 
group 
N/A 
 Street Vibes Community/Volunteering 
group 
N/A 




 Brand New Start Community/Volunteering 
group 
N/A 
 St Faith’s Centre Community/Volunteering 
group 
N/A 
 POstive Network Community/Volunteering 
group 
N/A 
 AccessAble Community/Volunteering 
group 
N/A 
 Global Woman.co Community/Volunteering 
group 
N/A 
 St Mary’s Tottenham Community/Volunteering 
group 
N/A 
 Aston Mansfield Community/Volunteering 
group 
N/A 
 Street Vibes Community/Volunteering 
group 
N/A 









 Arts Society Oxford Community/Volunteering 
group 
N/A 
 The Gatehouse Community/Volunteering 
group 
N/A 





















 Oxford Union Community/Volunteering 
group 
N/A 










 Teamherts  Community/Volunteering 
group 
N/A 





 Watford Mencap Community/Volunteering 
group 
N/A 




 Cedars youth and 




 Expressions Academy Community/Volunteering 
group 
N/A 





 iGNITE! Community/Volunteering 
group 
N/A 
 The Pavilion Community/Volunteering 
group 
N/A 
 Wembley PIWC Community/Volunteering 
group 
N/A 
 Elm Court Youth and 




 WEC Youth Camps Community/Volunteering 
group 
N/A 










 Willen Hospice Community/Volunteering 
group 
N/A 
 Age UK Milton Keynes Community/Volunteering 
group 
N/A 









 Willen Hospice Community/Volunteering 
group 
N/A 
 Liverpool City Council Community/Volunteering 
group 
N/A 
 LCVS  Community/Volunteering 
group 
N/A 





 Open Door Centre Community/Volunteering 
group 
N/A 
 The Cross Birkenhead Community/Volunteering 
group 
N/A 
 Bootle Christ Church 





















 Centre 63 Community/Volunteering 
group 
N/A 










 Mencap Liverpool Community/Volunteering 
group 
N/A 
 KCVS Community/Volunteering 
group 
N/A 





 Info Buzz Community/Volunteering 
group 
N/A 
 Vision 21 Community/Volunteering 
group 
N/A 





 Marah Community/Volunteering 
group 
N/A 
 Sheppard House Community/Volunteering 
group 
N/A 





























 Heart of Priors Park Community/Volunteering 
group 
N/A 
 Love Woodmancote Community/Volunteering 
group 
N/A 





 Suffol Young Farmers  Community/Volunteering 
group 
N/A 






  Pathways Care Group Community/Volunteering 
group 
N/A 








 Northampton Sikhs Community/Volunteering 
group 
N/A 





 Duston Parish Council Community/Volunteering 
group 
N/A 




















 Storehouse church Community/Volunteering 
group 
N/A 










 Glamis Hall for All Community/Volunteering 
group 
N/A 
 Victoria Centre Community/Volunteering 
group 
N/A 





 WACA Community/Volunteering 
group 
N/A 
 Olney Town council Community/Volunteering 
group 
N/A 
 New Start 4 u Community/Volunteering 
group 
N/A 
 Koco Community 




 Wild Earth Community/Volunteering 
group 
N/A 

























































 The gap  Community/Volunteering 
group 
N/A 










 Graham Adams Centre Community/Volunteering 
group 
N/A 
 Rugby West Indian 
Association social club 










 BHLC Community/Volunteering 
group 
N/A 
 Hinckley Natural 









  Churches of Arden Community/Volunteering 
group 
N/A 
 Cyrenians Community/Volunteering 
group 
N/A 
 St Basils Community/Volunteering 
group 
N/A 
 The Salvation Army Community/Volunteering 
group 
N/A 






















 Shenley Court Hall Community/Volunteering 
group 
N/A 











 Rowheath Pavilion Community/Volunteering 
group 
N/A 
 Endo ball Community/Volunteering 
group 
N/A 
 Welcome Change Community/Volunteering 
group 
N/A 
 Tekio Gemu Community/Volunteering 
group 
N/A 
 HPP Community/Volunteering 
group 
N/A 
 Clubmark Old Hill CC Community/Volunteering 
group 
N/A 





 Brierley Hill Project  Community/Volunteering 
group 
N/A 





 BVSC Community/Volunteering 
group 
N/A 
















 Oscar Sandwell Co. Ltd Community/Volunteering 
group 
N/A 






























 Lingwood Village Hall Community/Volunteering 
group 
N/A 
 Jubilee Family Centre Community/Volunteering 
group 
N/A 
  Hickling Barn Community/Volunteering 
group 
N/A 
 Reedham Village Hall Community/Volunteering 
group 
N/A 






























 Nuthall Parish Council Community/Volunteering 
group 
N/A 
 Hidden Disabilities Community/Volunteering 
group 
N/A 




















 The Victoria Centre Community/Volunteering 
group 
N/A 
 Changes Community/Volunteering 
group 
N/A 



















 Emmaus Sheffield Community/Volunteering 
group 
N/A 
 Tassibee  Community/Volunteering 
group 
N/A 
 Ashgate Hospicecare Community/Volunteering 
group 
N/A 
 St Paul’s church  Community/Volunteering 
group 
N/A 
 Richmond Church Community/Volunteering 
group 
N/A 
 The Link Community Community/Volunteering 
group 
N/A 











 Cornerstone Community/Volunteering 
group 
N/A 
 Salford CVS Community/Volunteering 
group 
N/A 
 ROC Community/Volunteering 
group 
N/A 
 Just add CIC Community/Volunteering 
group 
N/A 





 Rising Stars Community/Volunteering 
group 
N/A 





 Bury stars Community/Volunteering 
group 
N/A 





 HeartLift Community/Volunteering 
group 
N/A 
 The Hub Community/Volunteering 
group 
N/A 
 Castlemere Community/Volunteering 
group 
N/A 




 Barca-Leeds Community/Volunteering 
group 
N/A 
 YMCA Leeds Community/Volunteering 
group 
N/A 
 LS14 Trust Community/Volunteering 
group 
N/A 
 The Youth Association Community/Volunteering 
group 
N/A 
 Prism Youth Project  Community/Volunteering 
group 
N/A 
 Manningham Mills 










 Otley Courthouse Community/Volunteering 
group 
N/A 
 York Against Cancer Community/Volunteering 
group 
N/A 





 Burnley Pendle & 
Rossendale Council 




 Bristol Orbit Club  Community/Volunteering 
group 
N/A 
 Disabled Motoring UK  Community/Volunteering 
group 
N/A 
 WECIL  Community/Volunteering 
group 
N/A 






 Bristol Food Network Community/Volunteering 
group 
N/A 
 Park Work Community/Volunteering 
group 
N/A 





 Goodgym Community/Volunteering 
group 
N/A 
 Urban Buzz Bristol Community/Volunteering 
group 
N/A 
 Bristol Zero Tolerance Community/Volunteering 
group 
N/A 











 Walled Kitchen 




 Arnos Vale Community/Volunteering 
group 
N/A 





 Friends of Old Sneed 









 Bristol Social group Community/Volunteering 
group 
N/A 





 Bristol supper club  Community/Volunteering 
group 
N/A 
 Bristol & South 
Gloucestershire 




 National Vintage 









 Yogawest Community/Volunteering 
group 
N/A 
 Bristol & Bath Lug Community/Volunteering 
group 
N/A 










 Friends of BMGA, 
Supporting Bristol 











 Bristol Aero Club Community/Volunteering 
group 
N/A 





















 West Bristol Orchestra Community/Volunteering 
group 
N/A 
 Redland Wind Band  Community/Volunteering 
group 
N/A 
 City of Bristol College Community/Volunteering 
group 
N/A 
 South Gloucestershire 




 City of Bristol College Community/Volunteering 
group 
N/A 
 CUSU BME Campaign Student group N/A 
 Bristol University 
BME Success 
Student group N/A 





























Appendix 3.5     Questions eliminated from each section following Cronbach’s 
alpha test of reliability. 
 
[Section 1 - Biological knowledge of genetics] 
 







16. Approximately how many genes does the human DNA code contain?  
• 2,000  
• 1 million  
• 3 billion  
• 20,000 
 
19, 20, 22. On a scale of 0-100 how important do you think genetic differences are between 
people in explaining individual differences in the following traits (with 100 = only genetic 





 [Clinical knowledge of genetics in healthcare] 
 
2 There are many common diseases where the study of genetics can show the road to better 
treatment 
• True  
• False 
 
3. The use of genetics in healthcare can mean that expensive drugs are only given to those who 
will benefit from them 




4.  It is against the law for a doctor to not disclose a patient’s genetic test results to their close 
relatives as, given their genetic relatedness, the results may also concern them  
• True  
• False 
 
5. Currently, treatment for cancer can include a genetic diagnosis to show if a tumour might 
respond to a certain treatment 
• True  
• False 
 
6. The use of patients’ genetic data to deliver targeted therapies is already changing people’s 
lives 
• True  
• False 
 
7. A patient will only speak with a genetic counsellor if their genetic test result indicates they 
have a genetic predisposition to a disease 
• True  
• False 
 
8. Through a number of genetic testing techniques, it is possible to detect genetic abnormalities 
in an unborn child 
• True  
• False 
 
11. At present in the UK, new born infants are tested for certain genetic traits  














Appendix 3.6      Results for the data screening process. 
 





















Linearity plot between the biological knowledge of genetics measure and acceptance of 














































































































































































































Acceptance of genomic medicine 





































































































































































Regression standardised predicted value 













































































































Acceptance of genomic medicine 























































































School of Psychological Science 
12a Priory Road 
Bristol BS8 1TU 
Telephone: (0117) 928 9000 
 
 
21st February 2019 
 
Miss Helena Davies 
School of Psychological Sciences 
 
Dear Miss Davies, 
 
Ref: 77803 
Thoughts from the UK public on the use of genetics in healthcare: Concerns, expectations, and the 
provision of decision-relevant information 
 
The ethics committee have considered the above proposal which has received a conditional opinion 
requiring the following required changes to be seen by the chair of the committee: 
 
• The committee requested in the inclusion criteria that only adults are being recruited. 
• The committee noted that the study referred to taking place in a particular room within the 
Priory Road complex and thought it might allow for more flexibility if the application states that 
any room in Priory Road complex will be used to avoid needing an amendment just to interview 
in another room. 
• The committee requested clarification that a risk assessment has been conducted. 
• The committee noted that in the study documentation sometimes the time taken is said to be 
30-40 minutes, sometimes it is mentioned to be 1 hour. 
• The committee noted the monetary compensation for study participation and advised that 
generally speaking the rate for study participation is £10 a hour. 
• The committee advised that when questions regarding gender are asked it is preferable to have 
the question as a free text box for participants to write in what they identify as rather than a 
choice of particular options. 
• The applicants don’t mention how long audio-recordings will be kept (i.e., when audio-
recordings will be transcribed, and if/when the audio-recordings will be destroyed).  
• The committee observed that the researcher doesn’t appear to mention what device will be 
used to record interviews and recommended something that is encrypted and secure for 
vulnerable data. 
• The committee noted the PIS mentions Faculty of “Life Science” instead of “Psychological 
Science” Research Ethics Committee and wants this to be updated to reflect the new faculty 
structure at the university and structure of ethics committees accordingly. 
• The committee noted the distinction between study A and study B and wanted it clarified that 
both studies are being recorded and whether there is a final consent form for study A as well as 













21st February 2019  
 
Dr. Jonathan Evans 
Chair- School of Psychological Science Research Ethics Committee  
 
Dear Dr. Evans, 
 
Thank you for your response regarding my ethics application (Ref: 77803) Thoughts from 
the UK public on the use of genetics in healthcare: Concerns, expectations, and the 
provision of decision-relevant information.  
 
Below I have outlined the required changes and how I have addressed them. Please see 
attached for the amended documents – all changes have been tracked. 
 
• The committee requested in the inclusion criteria that only adults are being recruited.  
Addressed: In the ‘Full ethics’ document, I have amended question 8 regarding who will be 
recruited to participate, so that it reads ‘Adults (over 18 years of age), who are UK residents 
and have English as their first language or an equivalent level of fluency’. 
 
• The committee noted that the study referred to taking place in a particular room 
within the Priory Road complex and thought it might allow for more flexibility if the 
application states that any room in Priory Road complex will be used to avoid 
needing an amendment just to interview in another room.  
Addressed: : In the ‘Full ethics’ document, I have amended question 12 regarding where the 
research will take place, so that it reads ‘University of Bristol, in any room within the Priory 
Road complex’. 
 
• The committee requested clarification that a risk assessment has been conducted.  
Addressed: I have attached the out of hours risk assessment for Study A which has been 
submitted and approved by the School of Psychological Science. I have also attached the risk 
assessment for Study B. This is yet to be sent to the School of Psychological Science as I am 
conducting Study A first.  
 
• The committee noted that in the study documentation sometimes the time taken is 
said to be 30-40 minutes, sometimes it is mentioned to be 1 hour.  
Addressed: I have made the necessary changes in the Study B documents, so that it now 
indicates the study will take 1 hour.   
 
• The committee noted the monetary compensation for study participation and 
advised that generally speaking the rate for study participation is £10 a hour.  
Addressed: I have made the necessary changes in both Study A and Study B documents, so 
that it is now clear that the participants will be reimbursed £10 for their time. 
 
• The committee advised that when questions regarding gender are asked it is 
preferable to have the question as a free text box for participants to write in what 
they identify as rather than a choice of particular options.  
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SCHOOL OF PSYCHOLOGICAL SCIENCES 
12a Priory Road 
Bristol BS8 1TU 
Telephone: (0117) 928 9000 
 
 
9th April 2019 
 
Miss Helena Davies 





Title: Amendment 1 - Thoughts from the UK public on the use of genetics in healthcare: Concerns, 
expectations, and the provision of decision-relevant information 
 
Thank you for providing the following changes to your ethics proposal as detailed in your email dated 
02.04.19: 
 
These changes have been reviewed by the Chair of the ethics committee and approved. Your ethics 
approval code remains 31011977803. 
 
Good luck with the continuation of your study. 
 
Nathan Street 




Dr. Jonathan Evans 
Chair- School of Psychological Sciences Human Research Ethics Committee 
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Appendix 5      Question guide for the focus groups. 
 
 
• Would you have your genetic data tested by the NHS if you were at risk for a single gene 
(monogenic disorder)? 
 
• Would you have your genetic data tested by the NHS if you were trying for a baby and 
wanted to know your carrier status? 
 
• Would you have your genetic data tested by the NHS you were at risk of carrying a high 
penetrance mutation? 
 
• Would you have your genome sequenced by the NHS if you were told that knowledge of 
your genetic data may improve the effectiveness of a medical intervention that you 
required? 
 
• Would you want to know any information about your genetic sequence other than the 
specific genetic variant under investigation? 
 
Do you agree or disagree with the following statements: 
 
• ‘I am optimistic about the possibility of medical discoveries as a result of genetic 
research’ 
 
• ‘I expect medical professionals to consult me if a genetically related family member is 
having a genetic test’ 
 
• ‘I expect genetically related family members to consult me if they are having a 
genetic test’ 
 
• ‘I would be willing to share my anonymised patient record for medical research 
purposes’ 
 
• ‘I would be willing to share my anonymised genetic data for medical research 
purposes’ 
 
• ‘I feel suspicious about genetic studies for the improvement of health: hidden political 
or economic agendas may be behind them’ 
 
• ‘I would like to hear more information from scientists and healthcare professionals 
about genomic medicine’ 
 
What do you agree with most? 
 
• ‘The use of genetic data to inform medical research is overly intrusive’ OR ‘The use of 




• ‘I would be more concerned about my genetic data being leaked than my credit card 
information’ OR ‘I would be more concerned about my credit card information 
being leaked than my genetic data’ 
 
• ‘For me, DNA information is the same as any other medical information’ OR ‘For me, 
DNA information is different to other medical information’ 
 
Imagine yourself in the following scenario… 
 
• You have an opportunity to have a genetic test that may reveal that you are going to 
develop a condition that currently does not have any medical treatment options… What do 
you agreee with most? 
 
Knowledge is power: I would rather have the genetic test, so that I can prepare financially, 
emotionally, and practically if I am found to have a genetic variant that will lead to a 
(currently) incurable disease  OR  Ignorance is bliss: I would rather not have the genetic test, 
because if I am found to have a genetic variant that will lead to a (currently) incurable disease, 
I would worry about it too much to be able to carry on enjoying my life to the full 
 
Finish this sentence: 
 
• ‘I am most concerned about…’  
 















































































































































Appendix 7      Coding tree for qualitative study. 
 
 
Detrimental psychological impact of results 
Anxiety for self 
Anxiety for family members 
Hypochondria  
“Waiting for it to happen” 
Power of the mind 
Disclosure and discrimination  
Importance of anonymity  
Discrimination from organisations (insurance, employers) 
Status as a romantic partner 
Crime & the police 
Family planning 
Preparation – informed decision making 
Remaining uninformed  
Pressure to not start family 
Charting possible futures 
Genetic modification 
New ideas & suggestions for the future system of genomics 
Genetic exceptionalism: “DNA is different” 
Genome linked to identity 
“Playing God” 
Lack of privacy 
Intrusiveness of genetic data  
Knowledge is power 
Tailored treatment 
Mental preparedness 
Cherishing the time that you have 
Practical preparation 
Effective preparation for illness 
The ‘greater good’ 
 
 
 
 
 
 
 
 
